<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3110211250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SOVIRA 400 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOFOSBUVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5600
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AP08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SOVIRA contains the active substance sofosbuvir which is given to treat hepatitis C virus infection in adults and adolescents from the age of 12 years up to the age of 18 years. Hepatitis C is a virus that infects the liver. This medicine works by lowering the amount of hepatitis C virus in your body and removing the virus from your blood over a period of time.</p><p>SOVIRA is always taken with other medicines to treat hepatitis C. It will not work on its own. It is commonly taken with either: &bull; Ribavirin, or &bull; Peginterferon alfa and ribavirin. It is very important that you also read the leaflets for the other medicines that you will be taking with SOVIRA. If you have any questions about your medicines, please ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>Do not take SOVIRA</em></strong></p><p>&bull; If you are allergic to sofosbuvir or any of the other ingredients of this medicine (listed in section 6 of this leaflet). If this applies to you, tell your doctor immediately. &bull; If you are currently taking any of the following medicines: o Rifampicin (antibiotic used to treat infections, including tuberculosis); o St. John&rsquo;s wort (herbal medicine used to treat depression); o Carbamazepine, phenobarbital and phenytoin (medicines used to treat epilepsy and prevent seizures).</p><p><strong>Warnings and precautions</strong></p><p>SOVIRA is always taken with other medicines (see section 1 above). Talk to your doctor or pharmacist before taking this medicine if you: &bull; Currently take, or have taken in the last few months, the medicine amiodarone to treat irregular heartbeats (your doctor may consider alternative treatments if you have taken this medicine); &bull; Have liver problems other than hepatitis C, e.g. if you are awaiting a liver transplantation; &bull; Have a current or previous infection with the hepatitis B virus, since your doctor may want to monitor you more closely; &bull; Have diabetes. You may need closer monitoring of your blood glucose levels and/or adjustment of your diabetes medication after starting SOVIRA. Some diabetic patients have experienced low sugar levels in the blood (hypoglycaemia) after starting treatment with medicines like SOVIRA. &bull; A reduction of GFR has been observed during the use sofosbuvir in post marketing setting. Therefore, we recommend to monitor renal function at baseline and after 4 weeks of therapy and as clinically indicated. When Sofobuvir is used in combination with ribavirin or peginterferon alfa, please refer to the prescribing information of peginterferon alfa and ribavirin for patients with CrCl &lt;50 mL/min.</p><p>Tell your doctor immediately if you are taking any medicines for heart problems and during treatment you experience: &bull; Shortness of breath or worsening of any shortness of breath you already have. &bull; Light-headedness. &bull; Palpitations. &bull; Fainting. Blood tests Your doctor will test your blood before, during and after your treatment with SOVIRA. This is so your doctor can: &bull; Decide what other medicines you should take with SOVIRA and for how long; &bull; Confirm that your treatment has worked and you are free of the hepatitis C virus. Children and adolescents Do not give this medicine to children under 12 years of age. The use of SOVIRA in children under 12 years of age has not yet been studied. Other medicines and SOVIRA Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Warfarin and other similar medicines called vitamin K antagonists used to thin the blood. Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot. Your liver function may change with treatment of hepatitis C and therefore may affect other medications (e.g. medicines used to suppress your immune system, etc.). Your doctor may need to closely monitor these other medicines you are taking and make adjustments after starting SOVIRA. Talk to your doctor about taking SOVIRA if you are taking any of the following medicines: &bull; Oxcarbazepine (a medicine used to treat epilepsy and prevent seizures); &bull; Modafinil (a medicine to treat people with narcolepsy to help them stay awake). &bull; Rifapentine (a medicine used to treat infections, including tuberculosis); This is because they may make Sovira work less well.</p><p>Tell your doctor if you take any of the following medicines: &bull; amiodarone, used to treat irregular heartbeats.If you are not sure of what medicines can be taken with SOVIRA, talk to your doctor or pharmacist.</p><p><strong>Pregnancy and contraception</strong></p><p>Pregnancy must be avoided due to the use of SOVIRA together with ribavirin. Ribavirin can be very damaging to an unborn baby. Therefore, you and your partner must take special precautions in sexual activity if there is any chance for pregnancy to occur.</p><p>&bull; <strong>SOVIRA </strong>is commonly used together with ribavirin. Ribavirin can damage your unborn baby. It is therefore very important that you (or your partner) do not become pregnant during this therapy. &bull; You or your partner must use an effective birth control method during treatment and afterwards. It is very important that you read the &ldquo;Pregnancy&rdquo; section in the ribavirin package leaflet very carefully. Ask your doctor for effective contraceptive method suitable for you. &bull; If you or your partner becomes pregnant during SOVIRA treatment or in the months that follow, you must contact your doctor immediately. Breast-feeding You should not breast-feed during treatment with SOVIRA. It is not known whether sofosbuvir, the active substance of SOVIRA, passes into human breast milk.</p><p><strong>Driving and using machines</strong></p><p>When taking SOVIRA together with other medicines for the treatment of hepatitis C infection, patients have reported tiredness, dizziness, blurred vision and reduced attention. If you have any of these side effects, do not drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Recommended dose The recommended dose is one tablet (400 mg) once a day with food. Your doctor will tell you for how long you should take <strong>SOVIRA</strong>. Swallow the tablet whole. Do not chew, crush or split the tablet as it has a very bitter taste. Tell your doctor or pharmacist if you have problems swallowing tablets.</p><p>SOVIRA should always be taken in combination with other medicinal products for use against hepatitis C. If you are sick (vomit) less than 2 hours after taking SOVIRA, take another tablet. If you vomit more than 2 hours after taking it you do not need to take another tablet until your next regularly scheduled tablet.</p><p>If you take more SOVIRA than you should</p><p>If you accidentally take more than the recommended dose you should contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.</p><p><strong>If you forget to take SOVIRA</strong></p><p>It is important not to miss a dose of this medicine. If you do miss a dose: &bull; and you notice within 18 hours of the time you usually take SOVIRA, you must take the tablet as soon as possible. Then take the next dose at your usual time. &bull; and you notice 18 hours or more after the time you usually take SOVIRA, wait and take the next dose at your usual time.</p><p>Do not take a double dose (two doses close together).</p><p><strong>Do not stop taking SOVIRA</strong></p><p>Do not stop taking this medicine unless your doctor tells you to. It is very important that you complete the full course of treatment to give the medicines the best chance to treat your hepatitis C virus infection. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. When you take SOVIRA in combination with amiodarone (a medicine used for heart problems), you may get one or more of the side effects below: &bull; slow or irregular heartbeat or heart rhythm problems. &bull; shortness of breath or worsening of any shortness of breath you already have. Tell your doctor or your pharmacist if you notice any of the above side effects during therapy.</p><p>When you take SOVIRA with ribavirin or both peginterferon alfa and ribavirin, you may get one or more of the side effects below: Very common side effects (may affect more than 1 in 10 people) &bull; Fever, chills, flu-like symptoms. &bull; Diarrhoea, feeling sick (nausea), being sick (vomiting). &bull; Trouble sleeping (insomnia). &bull; feeling tired and irritable. &bull; Headache. &bull; Rash, itchy skin. &bull; Loss of appetite. &bull; Feeling dizzy. &bull; Muscle aches and pains, pain in the joints. &bull; Shortness of breath, cough. Blood tests may also show: &bull; Low red blood cell count (anaemia); the signs may include feeling tired, headaches, shortness of breath when exercising. &bull; Low white blood cell count (neutropenia); the signs may include getting more infections than usual, including fevers and chills, or sore throat or mouth ulcers. &bull; Low blood platelet count. &bull; Changes in your liver (as shown by increased amounts of a substance called bilirubin in the blood). Common side effects (may affect up to 1 in 10 people) &bull; Changes in your mood, feeling depressed, feeling anxious and feeling agitated. &bull; Blurred vision. &bull; Severe headaches (migraine), memory loss, loss of concentration. &bull; Weight loss. &bull; Shortness of breath when exercising. &bull; Stomach discomfort, constipation, dry mouth, indigestion, acid reflux. &bull; Hair loss and thinning hair. &bull; Dry skin. &bull; Back pain, muscle spasms. &bull; Chest pain, feeling weak. &bull; Getting a cold (nasopharyngitis).</p><p>Other effects that may be seen during treatment with sofosbuvir: The frequency of the following side effects is not known (frequency cannot be estimated from the available data). - a wide-spread severe rash with peeling skin which may be accompanied by fever, flulike symptoms, blisters in the mouth, eyes, and/or genitals (Stevens-Johnson syndrome). If any of the side effects get serious tell your doctor. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side affects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Do not store above 30&ordm;C. &bull; Keep out of the sight and reach of children. &bull; Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}. The expiry date refers to the last day of that month. &bull; This medicine will be expired after 28 days after opening the bottle. &bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is sofosbuvir. Each film-coated tablet contains 400 mg of sofosbuvir. The other ingredients are Tablet core: Mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate. Film-coating: Opadry yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pale yellow to yellow, oblong biconvex film-coated tablets, engraved with "712" on one
side and plain on the other side.
SOVIRA tablets are supplied in a carton box containing plastic HDPE bottle (containing
28 film-coated), desiccant and leaflet. The plastic bottle is aluminium sealed and closed
with a plastic HDPE cap.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO Al-Qassim pharmaceutical plant Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سوڤیرا یحتوي على المادة الفعالة سوفوسبوڤیر التي تستخدم لعلاج عدوى الالتھاب الكبدي الفیروسي نوع (سي) في البالغین و المراھقین من سن 12 سنة حتى سن 18 سنة. الالتھاب الكبدي الفیروسي نو ع (سي) ھو عبارة عن فیروس یصیب الكبد. ھذا الدواء یعمل عن طریق خفض كمیة فیروس الالتھاب الكبدي سي في الجسم و إزالة الفیروس من الدم خلال فترة من الزمن.</p><p>یتم تناول سوڤیرا دائما مع الأدویة الأخرى التي تعالج الالتھاب الكبدي الفیروسي نوع (سي) حیث انھ لا یعمل منفردا و یتم تناولھ عادة مع: &bull; ریبافیرین، أو &bull; بیج انترفیرون ألفا و ریبافیرین. من المھم جدا أن تقرأ أیضا نشرات الأدویة الأخرى التي سوف تتناولھا مع سوڤیرا. اذا كانت لدیك أي أسئلة حول الأدویة الخاصة بك، یرجى التحدث مع طبیبك أو الصیدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال سوڤیرا لا تتناول سوڤیرا: &bull; إذا كان لدیك حساسیة من سوفوسبوڤیر أو أي من المكونات الأخرى في ھذا الدواء. انظر الفقرة 6 من ھذه النشرة إذا كان ھذا ینطبق علیك، أخبر طبیبك فورا. &bull; إذا كنت تتناول حالیا أي من ھذه الأدویة &bull; ریفامبیسین ( مضاد حیوي یستخدم لعلاج العدوي، بما في ذلك الدرن)، &bull; نبتة سانت جون (دواء عشبي یستخدم لعلاج الاكتئاب)، &bull; كاربامازیبین أو فیینوباربیتال أو الفینتوین ( الأدویة المستخدمة في علاج الصرع و منع النوبات). المحاذیر والاحتیاطات یتم تناول سوڤیرا دائما مع أدویة أخري (انظر الفقرة 1 .(تحدث إلى طبیبك أو الصیدلي قبل تناول ھذا الدواء إذا كنت: &bull; تتناول حالیا أو في الأشھر القلیلة الأخیرة، دواء أمیودارون لعلاج ضربات القلب الغیر منتظمة (قد یصف الطبیب لك دواء بدیل في حالة تناولك ھذا الدواء)، &bull; لدیك مشاكل في الكبد غیر الالتھاب الكبدي سي، على سبیل المثال إذا كنت في انتظار عملیة زراع ة الكبد، &bull; لدیك إصابة حالیة أو سابقة بفیروس الالتھاب الكبدي بي، حیث یجب على طبیبك متابعتك عن قرب أكثر، &bull; كنت مصابا بمرض السكري. قد تحتاج إلى متابعة دقیقة لمستویات السكر في الدم و/ أو تعدیل دواء السكري الخاص بك بعد بدء سوڤیرا. تعرض بعض مرضى السكر إلي انخفاض مستویات السكر في الدم بعد بدء العلاج بأدویة مثل سوڤیرا. &bull; لوحظ انخفاض معدل الترشیح الكبیبي أثناء استخدام سوفوسبوڤیر في حالات ما بعد التسویق. لذلك، نوصي ًا. عند استخدام بمراقبة وظائف الكلى عند بدایة العلاج وبعد 4 أسابیع من العلاج وكما ھو محدد سریری سوفوسبوڤیر مع ریبافیرین أو بیج انترفیرون، یرجى الرجوع إلى معلومات وصف ریبافیرین و بیج انترفیرون للمرضى الذین یعانون من معدل تصفیة الكریاتینین (CrCl (أقل من 50 مل/دقیقة. أخبر طبیبك فورا إذا كنت تتنا ول أي أدویة لعلاج أمراض القلب وخلال العلاج عانیت من الأتي:</p><p>&bull; ضیق في التنفس أو تفاقم أي ضیق في التنفس تعاني منھ بالفعل. &bull; دوار. &bull; خفقان. &bull; إغماء. اختبارات الدم سوف یقوم طبیبك باجراء اختبار الدم قبل و أثناء و بعد العلاج بدواء سوڤیرا، و بھذا یمكن للطبیب أن: &bull; یقرر الأدویة الأخرى التي یجب تناولھا مع سوڤیرا و فترة العلاج ، &bull; یتأكد من أن العلاج قد تم و أنك قد تخلصت من فیروس التھاب الكبد سي. الأطفال و المراھقین لا تعطي ھذا الدواء للأطفال دون سن 12 سنة. لم تتم دراسة استخدام سوڤیرا في الأطفال دون سن 12 سنة. الأدویة الأخري وسوڤیرا أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرا أو من الممكن أن تتناول أي أدویة أخري. الوارفارین وأدویة أخرى مماثلة تسمى مضادات فیتامین ك المستخدمة لزیاده سیولة الدم .قد یحتاج طبیبك إلى زیادة معدل تكرار اختبارات الدم للتحقق من مدى كفاءة تجلط الدم لدیك . قد تتغیر وظائف الكبد مع تناول علاج التھاب الكبد الوبائي سي وبالتالي قد تؤثر على الأدویة الأخرى (مثل الأدویة المستخدمة لتقلیل نظام المناعة لدیك، وغیرھا من الأدویة). قد یحتاج طبیبك إلى متابعة الأدویة الأخرى التي تتناولھا عن كثب وإجراء التعدیلات بعد بدء سوڤیرا. تحدث مع طبیبك حول تناول سوڤیرا إذا كنت تتناول أي من الأدویة التالیة: &bull; اوكسكاربازیبین (دواء یستخدم لعلاج الصرع ومنع النوبات)؛ &bull; مودافینیل (دواء لعلاج الأشخاص الذین یعانون من حالة الخدار لمساعدتھم على البقاء مستیقظین). &bull; ریفابنتین (دواء یستخدم لعلاج العدوي، بما في ذلك السل). حیث أنھا قد تقلل من كفاءة عمل سوڤیرا. أخبر طبیبك إذا كنت تتناول أي من الأدویة التالیة: &bull; امیودارون، ویستخدم لعلاج عدم انتظام ضربات القلب. إذا كنت غیر متأكد من الأدویة التي یمكن تناولھا مع سوڤیرا، تحدث إلى طبیبك أو الصیدلي. الحمل و منع الحمل یجب تجنب الحمل أثناء استخدام سوڤیرا جنبا إلى جنب مع ریبافیرین. ریبافیرین یمكن أن یكون مضر جدا للجنین.</p><p>لذلك یجب أخذ الاحتیاطات الخاصة من جانبك ومن جانب شریكك أثناء العلاقة الجنسیة لمنع أي فرصة لحدوث الحمل. &bull; عادة یستخدم سوڤیرا جنبا إلى جنب مع ریبافیرین. و حیث أن ریبافیرین یمكن أن یلحق الضرر بالطفل قبل الولادة، لذا فمن المھم جدا ألا تصبحین حاملا خلال فترة العلاج. &bull; یجب استخدام وسیلة فعالة لمنع الحمل أثناء العلاج و بعد ذلك. من المھم جدا أن تقرأي الجزء الخاص بالحمل في النشرة الدوائیة الخاصة بالریبافیرین. اسألي طبیبك عن طریقة فعالة لمنع الحمل تكون مناسبة لك. &bull; یجب علیك الاتصال بطبیبك على الفور عند حدوث حمل أثناء تناول سوڤیرا أو في الأشھر التالیة للعلاج. الرضاعة الطبیعیة یجب إیقاف الرضاعة أثناء العلاج ب سوڤیرا. حیث انھ من غیر المعروف ما إذا كان سوفوسبوڤیر ( المادة الفعالة لدواء سوڤیرا ) یمر في حلیب الثدي. تأثیر سوڤیرا على القیادة و استخدام الآلات تم رصد حالات من التعب و الدوخة، و عدم وضوح الرؤیة و انخفاض التركیز في المرضى الذین یتناولون سوڤیرا جنبا إلى جنب مع غیرھا من الأدویة لعلاج عدوى الالتھاب الكبدي سي. إذا كانت لدیك أي من ھذه الأعراض الجانبیة، فلا تقوم بالقیادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما قم بتناول ھذا الدواء تماما كما وضح لك طبیبك. استشر طبیبك أو الصیدلي إذا لم تكن متأكدا. الجرعة الموصي بھا الجرعة الموصى بھا ھي قرص واحد ( 400 ملجم) مرة واحدة یومیا مع الطعام. سوف یوضح لك طبیبك إلى متى یجب أن تتناول سوڤیرا. یجب ابتلاع القرص بأكملھ بدون مضغ أو سحق أو تقسیم القرص حیث أن لھ طعم شدید المرارة. أخبر طبیبك أو الصیدلي إذا كانت لدیك مشاكل في بلع الأقراص. ینبغي دائما أن تتناول سوڤیرا مع الأدویة الأخرى التي تستخدم لعلاج الالتھاب الكبدي الفیروسي سي. إذا تعرضت للقئ بعد أقل من ساعتین من تناول سوڤیرا، یجب أن تتناول قرص أخر. إذا تعرضت للقئ بعد أكثر من ساعتین من تناول سوڤیرا فأنت لا تحتاج لتناول قرص أخر حتى یحین موعد القرص التالي. إذا تناولت سوڤیرا أكثر مما ینبغي إذا تناولت عن غیر قصد أكثر من الجرعة الموصى بھا یجب علیك الاتصال بالطبیب أو أقرب قسم للطوارئ على الفور للحصول على المشورة وقم بالاحتفاظ بعلبة الأقراص حتى تستطیع وصف ما الذي تناولتھ.</p><p>إذا نسیت تناول سوڤیرا من المھم عدم نسیان تناول جرعة ھذا الدواء. اذا نسیت تناول الجرعة: &bull; ولاحظت ذلك في غضون 18 ساعة من الوقت الذي عادة ما تتناول فیھ الجرعة، یجب أن تتناول ال قرص في أقرب وقت ممكن. ثم تناول الجرعة التالیة في الوقت المعتاد الخاص بھا. &bull; أما إذا لاحظت ذلك بعد مرور 18 ساعة أو أكثر بعد الوقت الذي عادة ما تتناول فیھ جرعة سوڤیرا، فعلیك أن تنتظر و تتناول الجرعة التالیة في الوقت المعتاد الخاص بھا. لا تتناول جرعة مضاعفة (تناول جرعتین بالقرب من بعضھما البعض ). لا تتوقف عن تناول سوڤیرا لا تتوقف عن تناول ھذا الدواء ما لم یخبرك طبیبك. ومن المھم جدا أن تقوم بإتمام فترة العلاج بالكامل لإعطاء الأدویة أفضل فرصة لعلاج التھاب الكبد الوبائي سي. إذا كانت لدیك أي أسئلة أخرى عن استخدام ھذا الدواء، أسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة، یمكن لھذا الدواء أن یسبب أعراضا جانبیة، و إن لم تكن تحدث للجمیع. عندما تتناول سوڤیرا مع أمیودارون (دواء یستخدم لعلاج مشاكل القلب)، فقد تظھر علیك واحدة أو أكثر من الأعراض الجانبیة التالیة: &bull; نبضات بطیئة أو غیر منتظمة أو مشاكل في ضربات القلب. &bull; ضیق التنفس أو تفاقم أي ضیق في التنفس لدیك بالفعل. أخبر طبیبك أو الصیدلي إذا لاحظت أي من الأعراض الجانبیة المذكورة أعلاه أثناء العلاج. عندما تتناول سوڤیرا مع ریبافیرین أو مع كل من بیج انترفیرون و ریبافیرین، قد تحدث أي من الأعراض الجانبیة التالیة: الأعراض الجانبیة الشائعة جدا ( قد تؤثر على أكثر من 1 من كل 10 أشخاص) &bull; حمي، قشعریرة، و أعراض تشبھ الانفلوانزا. &bull; الإسھال، و الشعور بالإعیاء (الغثیان)، و المرض (القئ). &bull; مشاكل في النوم (الأرق). &bull; الشعور بالتعب و سرعة الانفعال. &bull; صداع.&bull; طفح جلدي، حكة في الجلد. &bull; فقدان الشھیة. &bull; الشعور بالدوار. &bull; آلام و أوجاع في العضلات، و آلام في المفاصل. &bull; ضیق في التنفس، و السعال. اختبارات الدم قد تبین أیضا: &bull; انخفاض عدد خلایا الدم الحمراء (فقر الدم)، و الأعراض قد تشمل الشعور بالتعب و الصداع، و ضیق التنفس عند ممارسة الریاضة. &bull; انخفاض عدد خلایا الدم البیضاء، و الأعراض قد تشمل حدوث الإصابة بالعدوى أكثر من المعتاد، بما في ذلك الحمى و الرعشة، أو التھاب الحلق أو قرح الفم. &bull; انخفاض عدد الصفائح الدمویة في الدم. &bull; تغیرات في الكبد (زیادة كمیات مادة تسمى البیلیروبین في الدم ). الأعراض الجانبیة الشائعة ( قد تؤثر على ما یصل إلى 1 من كل 10 أشخاص ) &bull; تغیرات في المزاج، و الشعور بالاكتئاب، و الشعور بالقلق و الاضطراب. &bull; عدم و وضوح الرؤیة. &bull; صداع شدید (الصداع النصفي)، و فقدان الذاكرة، فقدان التركیز. &bull; فقدان الوزن. &bull; ضیق في التنفس عند ممارسة الریاضة. &bull; عدم الراحة في المعدة، و الإمساك، و جفاف الفم، و عسر الھضم، والارتجاع الحمضي. &bull; تساقط الشعر و ترقق الشعر. &bull; جفاف الجلد. &bull; آلام الظھر، التشنجات العضلیة. &bull; ألم في الصدر، و الشعور بالضعف. &bull; الإصابة بالبرد (التھاب البلعوم الأنفي ). الأعراض الأخرى التي یمكن ملاحظتھا أثناء العلاج باستخدام سوفوسبوڤیر: معدل تكرار الأعراض الجانبیة التالیة غیر معروف (لا یمكن تقدیر معدل تكرارھا من البیانات المتاحة). ًا بأعراض الحمى وأعراض شبیھة بالإنفلونزا - طفح جلدي واسع الانتشار مع ظھور جلد مقشر قد یكون مصحوب وبثور في الفم والعینین و/ أو الأعضاء التناسلیة (متلازمة ستیفنز جونسون). یجب أن تخبر طبیبك إذا أصبحت أي من الأعراض الجانبیة أكثر حدة. الإبلاغ عن الأعراض الجانبیة</p><p>&nbsp;إذا ظھرت علیك أي أعراض جانبیة، قم بالتحدث مع طبیبك أو الصیدلي أو الممرضة. ویشمل ذلك أي أعراض ُ جانبیة محتملة غیر المدرجة في ھذه النشرة. یمكنك أیضا الإبلاغ عن الأعراض الجانبیة مباشرة عبر المركز الوطني للتیقظ والسلامة الدوائیة. یمكنك من خلال الإبلاغ عن الأعراض الجانبیة أن تساعد في توفیر المزید من المعلومات حول سلامة ھذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; لا یحفظ في درجة حرارة أعلي من 30 درجة مئویة. &bull; یحفظ بعیدا عن متناول و نظر الأطفال. &bull; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور في الملصق والكرتون بعد{EXP .{و تاریخ الانتھاء یشیر إلى الیوم الأخیر من ذلك الشھر. &bull; تنتھي صلاحیة ھذا الدواء بعد 28 یوم من فتح العبوة. &bull; لا تتخلص من أي أدویة عن طریق میاه الصرف الصحي أو النفایات المنزلیة .اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد تستخدم .و سوف تساعد ھذه التدابیر على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;علام یحتوي سوڤیرا المادة الفعالة ھي سوفوسبوڤیر. كل قرص مغلف یحتوي على 400 ملجم من سوفوسبوڤیر. المكونات الأخرى نواة القرص: مانیتول، میكروكریستالین السیلیلوز، كروسكارمیلوز الصودیوم، السیلیكا اللامائیة الغروانیة، ستیرات الماغنیسیوم. الغلاف أوبادراي أصفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص صفراء إلى صفراء باھتة مستطیلة ومحدبة من الجانبین ومغلفة بطبقة رقیقة محفورة برقم &quot;712 &quot;على احدى الجوانب وجلیة السطح على الجانب الاخر. علبة كرتون تحتوي على عبوة بلاستیكیة بولي ایثیلین عالي الكثافة بھا 28 قرص مغلف، مجفف و نشرة داخلیة. العبوة البلاستیكیة مغطاة بغطاء الومنیوم ومغلقة بغطاء بلاستیكي من مادة البولي ایثیلین عالي الكثافة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائیة</p><p>مصنع الأدویة بالقصیم المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             أغسطس 2020 

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SOVIRA 400mg (Film-Coated) Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 400 mg of Sofosbuvir.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Pale yellow to yellow, oblong biconvex film-coated tablets, engraved with "712" on one side and
plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SOVIRA is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and in adolescents aged 12 to &lt;18 years (see sections 4.2, 4.4 and 5.1). For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SOVIRA treatment should be initiated and monitored by a physician experienced in the management of patients with CHC.</p><p><strong><u>Posology</u></strong></p><p>Adults The recommended dose is one 400 mg tablet, taken orally, once daily with food (see section 5.2). SOVIRA should be used in combination with other medicinal products. Monotherapy of SOVIRA is not recommended (see section 5.1). Refer also to the Summary of Product Characteristics of the medicinal products that are used in combination with SOVIRA. The recommended co-administered medicinal product(s) and treatment duration for SOVIRA combination therapy are provided in Table 1.</p><p><strong>Table 1: Recommended co-administered medicinal product(s) and treatment duration for adults treated with SOVIRA combination therapy</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:1018px"><tbody><tr><td style="width:352px">Patient population*</td><td style="width:164px">Treatment</td><td style="width:558px">Duration</td></tr><tr><td rowspan="2" style="width:352px">Patients with genotype 1, 4, 5 or 6 CHC</td><td style="width:164px">SOVIRA + ribavirin + peginterferon alfa</td><td rowspan="2" style="width:558px">&nbsp;24 weeks</td></tr><tr><td style="width:164px">SOVIRA + ribavirin Only for use in patients ineligible or intolerant to peginterferon alfa (see section 4.4)</td></tr><tr><td style="width:352px">Patients with genotype 2 CHC</td><td style="width:164px">SOVIRA + ribavirin</td><td style="width:558px">12 weeksb</td></tr><tr><td rowspan="2" style="width:352px">Patients with genotype 3 CHC</td><td style="width:164px">SOVIRA + ribavirin + peginterferon alfa</td><td style="width:558px">12 weeksb</td></tr><tr><td style="width:164px">SOVIRA + ribavirin</td><td style="width:558px">24 weeks</td></tr><tr><td style="width:352px">Patients with CHC awaiting liver transplantation</td><td style="width:164px">SOVIRA + ribavirin</td><td style="width:558px">Until liver transplantationc</td></tr></tbody></table><p>* Includes patients co-infected with human immunodeficiency virus (HIV). a. For previously treated patients with HCV genotype 1 infection, no data exists with the combination of SOVIRA, ribavirin and peginterferon alfa (see section 4.4). b. Consideration should be given to potentially extending the duration of therapy beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower response rates to interferon-based therapies (e.g. advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype, prior null response to peginterferon alfa and ribavirin therapy). c. See Special patient populations &ndash; Patients awaiting liver transplantation below</p><p>The dose of ribavirin, when used in combination with SOVIRA is weight-based (&lt;75 kg = 1,000 mg and &ge;75 kg = 1,200 mg) and administered orally in two divided doses with food. Concerning co-administration with other direct-acting antivirals against HCV, see section 4.4. Dose modification in adults Dose reduction of SOVIRA is not recommended. If sofosbuvir is used in combination with peginterferon alfa, and a patient has a serious adverse reaction potentially related to this medicinal product, the peginterferon alfa dose should be reduced or discontinued. Refer to the peginterferon alfa Summary of Product Characteristics for additional information about how to reduce and/or discontinue the peginterferon alfa dose. If a patient has a serious adverse reaction potentially related to ribavirin, the ribavirin dose should be modified or discontinued, if appropriate, until the adverse reaction abates or decreases in severity. Table 2 provides guidelines for dose modifications and discontinuation based on the patient&#39;s haemoglobin concentration and cardiac status.</p><p><strong>Table 2: Ribavirin dose modification guideline for co-administration with SOVIRA in adults</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:934px"><tbody><tr><td style="width:375px">Laboratory values</td><td style="width:108px">Reduce ribavirin dose to 600 mg/day if:</td><td style="width:448px">Discontinue ribavirin if:</td></tr><tr><td style="width:375px">Haemoglobin in patients with no cardiac disease</td><td style="width:108px">&lt;10 g/dL</td><td style="width:448px">&lt;8.5 g/dL</td></tr><tr><td style="width:375px">Haemoglobin in patients with history of stable cardiac disease</td><td style="width:108px">&ge;2 g/dL decrease in haemoglobin during any 4 week treatment period</td><td style="width:448px">&lt;12 g/dL despite 4 weeks at reduced dose</td></tr></tbody></table><p>Once ribavirin has been withheld due to either a laboratory abnormality or clinical manifestation, an attempt may be made to restart ribavirin at 600 mg daily and further increase the dose to 800 mg daily. However, it is not recommended that ribavirin be increased to the original assigned dose (1,000 mg to 1,200 mg daily).</p><p>Adolescents (12 to 18 years of age) The recommended dose of SOVIRA is one tablet once daily with food (see section 5.2). SOVIRA should be used in combination with other medicinal products. Monotherapy of SOVIRA is not recommended. The recommended treatment regimen and durations for SOVIRA combination therapy are provided in Table 3 and Table 4.</p><p><strong>Table 3: Recommended treatment regimen and durations for adolescents aged 12 to &lt; 18 years treated with SOVIRA</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:499.844px"><tbody><tr><td style="width:241px">Patient population*</td><td style="width:257px">Treatment and duration</td></tr><tr><td style="width:241px">Patients with genotype 2 CHC</td><td style="width:257px">SOVIRA + ribavirina for 12 weeks b</td></tr><tr><td style="width:241px">Patients with genotype 3 CHC</td><td style="width:257px">SOVIRA + ribavirin a for 24 weeks</td></tr></tbody></table><p>* Includes patients co infected with human immunodeficiency virus (HIV). a. See Table 4 for weight based ribavirin dosing recommendations b. Consideration should be given to potentially extending the duration of therapy beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower response rates to interferon based therapies (e.g. advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype, prior null response to peginterferon alfa and ribavirin therapy).</p><p><strong>Table 4: Recommended dosing for ribavirin in combination therapy with SOVIRA in adolescents aged 12 to &lt; 18 years</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:224px">Body weight kg (lbs)</td><td style="width:275px">RBV daily dose*</td></tr><tr><td style="width:224px">&lt;47 (&lt;103)</td><td style="width:275px">15 mg/kg/day</td></tr><tr><td style="width:224px">47-49 (103-108)</td><td style="width:275px">600 mg/day</td></tr><tr><td style="width:224px">50-65 (110-143)</td><td style="width:275px">800 mg/day</td></tr><tr><td style="width:224px">66-80 (145-176)</td><td style="width:275px">1000 mg/day</td></tr><tr><td style="width:224px">&gt;81 (178)</td><td style="width:275px">1200 mg/day</td></tr></tbody></table><p>* The daily dosage of ribavirin is weight-based and is administered orally in two divided doses with food.</p><p>&nbsp;</p><p>Dose modification in adolescents Dose reduction of SOVIRA is not recommended. If a patient has a serious adverse reaction potentially related to ribavirin, the ribavirin dose should be modified or discontinued, if appropriate, until the adverse reaction abates or decreases in severity. Refer to the ribavirin prescribing information for guidance on dose modification or discontinuation. Discontinuation of dosing in adults and adolescents If the other medicinal products used in combination with SOVIRA are permanently discontinued, SOVIRA should also be discontinued (see section 4.4). Vomiting and missed doses Patients should be instructed that if vomiting occurs within 2 hours of dosing an additional tablet should be taken. If vomiting occurs more than 2 hours after dosing, no further dose is needed. These recommendations are based on the absorption kinetics of sofosbuvir and GS-331007 suggesting that the majority of the dose is absorbed within 2 hours after dosing. If a dose is missed and it is within 18 hours of the normal time, patients should be instructed to take the tablet as soon as possible and then patients should take the next dose at the usual time. If it is after 18 hours then patients should be instructed to wait and take the next dose at the usual time. Patients should be instructed not to take a double dose. Special patient populations Elderly No dose adjustment is warranted for elderly patients (see section 5.2). Renal impairment No dosage adjustment of SOVIRA is recommended in patients with any degree of renal impairment, including end stage renal disease (ESRD) on dialysis. Take SOVIRA with or without ribavirin according to the recommendations. Refer to ribavirin tablet prescribing information for ribavirin dosage modification for patients with CrCl less than or equal to 50 mL per minute. Hepatic impairment No dose adjustment of SOVIRA is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh-Turcotte [CPT] class A, B or C) (see section 5.2). The safety and efficacy of SOVIRA have not been established in patients with decompensated cirrhosis.</p><p>Patients awaiting liver transplantation The duration of administration of SOVIRA in patients awaiting liver transplantation should be guided by an assessment of the potential benefits and risks for the individual patient (see section 5.1). Liver transplant recipients SOVIRA in combination with ribavirin is recommended for 24 weeks in liver transplant recipients. A starting ribavirin dose of 400 mg administered orally in two divided doses with food is recommended. If the starting dose of ribavirin is well-tolerated, the dose can be titrated up to a maximum of 1,000-1,200 mg daily (1,000 mg for patients weighing &lt;75 kg and 1,200 mg for patients weighing &ge;75 kg). If the starting dose of ribavirin is not well-tolerated, the dose should be reduced as clinically indicated based on haemoglobin levels (see section 5.1). Paediatric population The safety and efficacy of SOVIRA in children and adolescents aged &lt;12 years have not yet been established. No data are available. Method of administration Oral use. Patients should be instructed to swallow the tablet whole. The film-coated tablet should not be chewed or crushed, due to the bitter taste of the active substance. The tablet should be taken with food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Medicinal products that are strong P-glycoprotein (P-gp) inducers in the intestine
(carbamazepine, phenobarbital, phenytoin, rifampicin and St. John's wort). Co-administration
will significantly decrease sofosbuvir plasma concentration and could result in loss of efficacy of
SOVIRA (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General SOVIRA is not recommended for administration as monotherapy and should be prescribed in combination with other medicinal products for the treatment of hepatitis C infection. If the other medicinal products used in combination with SOVIRA are permanently discontinued, SOVIRA should also be discontinued (see section 4.2). Consult the Summary of Product Characteristics for co-prescribed medicinal products before starting therapy with SOVIRA.</p><p>Severe bradycardia and heart block Cases of severe bradycardia and heart block have been observed when sofosbuvir-containing regimens are used in combination with amiodarone with or without other medicinal products that lower heart rate. The mechanism is not established. The concomitant use of amiodarone was limited through the clinical development of sofosbuvir . Cases are potentially life threatening, therefore amiodarone should only be used in patients on SOVIRA when other alternative anti-arrhythmic treatments are not tolerated or are contraindicated. Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. Should concomitant use of amiodarone be considered necessary it is recommended that patients are closely monitored when initiating SOVIRA. Patients who are identified as being at high risk of bradyarrhythmia should be continuously monitored for 48 hours in an appropriate clinical setting. Due to the long half-life of amiodarone, appropriate monitoring should also be carried out for patients who have discontinued amiodarone within the past few months and are to be initiated on SOVIRA. All patients receiving SOVIRA in combination with amiodarone with or without other medicinal products that lower heart rate should also be warned of the symptoms of bradycardia and heart block and should be advised to seek medical advice urgently should they experience them. HCV/HBV (hepatitis B virus) co-infection Cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with direct-acting antiviral agents. HBV screening should be performed in all patients before initiation of treatment. HBV/HCV co-infected patients are at risk of HBV reactivation, and should therefore be monitored and managed according to current clinical guidelines. Treatment-experienced patients with genotype 1, 4, 5 and 6 HCV infection SOVIRA has not been studied in a Phase 3 study in treatment-experienced patients with genotype 1, 4, 5 and 6 HCV infection. Thus, the optimal treatment duration in this population has not been established (see also sections 4.2 and 5.1). Consideration should be given to treating these patients, and potentially extending the duration of therapy with sofosbuvir, peginterferon alfa and ribavirin beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower&nbsp;response rates to interferon-based therapies (advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype). Treatment of patients with genotype 5 or 6 HCV infection The clinical data to support the use of SOVIRA in patients with genotype 5 and 6 HCV infection is very limited (see section 5.1). Interferon-free therapy for genotype 1, 4, 5 and 6 HCV infection Interferon-free regimens for patients with genotype 1, 4, 5 and 6 HCV infection with SOVIRA have not been investigated in Phase 3 studies (see section 5.1). The optimal regimen and treatment duration have not been established. Such regimens should only be used for patients that are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment. Co-administration with other direct-acting antivirals against HCV SOVIRA should only be co-administered with other direct-acting antiviral medicinal products if the benefit is considered to outweigh the risks based upon available data. There are no data to support the co-administration of SOVIRA and telaprevir or boceprevir. Such co-administration is not recommended (see also section 4.5). Pregnancy and concomitant use with ribavirin When SOVIRA is used in combination with ribavirin or peginterferon alfa/ribavirin, women of childbearing potential or their male partners must use an effective form of contraception during the treatment and for a period of time after the treatment as recommended in the Summary of Product Characteristics for ribavirin. Refer to the Summary of Product Characteristics for ribavirin for additional information. Use with moderate P-gp inducers Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil, oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced therapeutic effect of SOVIRA. Co-administration of such medicinal products is not recommended with SOVIRA (see section 4.5). Use in diabetic patients Diabetics may experience improved glucose control, potentially resulting in symptomatic hypoglycaemia, after initiating HCV direct-acting antiviral treatment. Glucose levels of diabetic patients initiating direct-acting antiviral therapy should be closely monitored, particularly within the first 3 months, and their diabetic medication modified when necessary. The physician in charge of the diabetic care of the patient should be informed when direct-acting antiviral therapy is initiated.</p><p>Renal impairment No dosage adjustment of SOVIRA is recommended in patients with any degree of renal impairment, including end stage renal disease (ESRD) on dialysis. A reduction of GFR has been observed during the use sofosbuvir in post marketing setting. Therefore, we recommend to monitor renal function at baseline and after 4 weeks of therapy and as clinically indicated. When Sofobuvir is used in combination with ribavirin or peginterferon alfa, please refer to the prescribing information of peginterferon alfa and ribavirin for patients with CrCl &lt;50 mL/min.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sofosbuvir is a nucleotide prodrug. After oral administration of SOVIRA, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic and intestinal metabolism. Intracellular hydrolytic prodrug cleavage catalysed by enzymes including carboxylesterase 1 and sequential phosphorylation steps catalysed by nucleotide kinases result in formation of the pharmacologically active uridine nucleoside analogue triphosphate. The predominant inactive circulating metabolite GS-331007 that accounts for greater than 90% of drug-related material systemic exposure is formed through pathways sequential and parallel to formation of active metabolite. The parent sofosbuvir accounts for approximately 4% of drug-related material systemic exposure (see section 5.2). In clinical pharmacology studies, both sofosbuvir and GS331007 were monitored for purposes of pharmacokinetic analyses. Sofosbuvir is a substrate of drug transporter P-gp and breast cancer resistance protein (BCRP) while GS-331007 is not. Medicinal products that are strong P-gp inducers in the intestine (carbamazepine, phenobarbital, phenytoin, rifampicin and St. John&#39;s wort) may significantly decrease sofosbuvir plasma concentration leading to reduced therapeutic effect of SOVIRA and thus are contraindicated with SOVIRA (see section 4.3). Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil, oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced therapeutic effect of SOVIRA. Co-administration with such medicinal products is not recommended with SOVIRA (see section 4.4). Co-administration of SOVIRA with medicinal products that inhibit P-gp and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma concentration, thus SOVIRA may be coadministered with P-gp and/or BCRP inhibitors. Sofosbuvir and GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of medicinal products that are substrates of these transporters. The intracellular metabolic activation pathway of sofosbuvir is mediated by generally low affinity and high capacity hydrolase and nucleotide phosphorylation pathways that are unlikely to be affected by concomitant medicinal products (see section 5.2).</p><p>Patients treated with vitamin K antagonists As liver function may change during treatment with SOVIRA, a close monitoring of International Normalised Ratio (INR) values is recommended. Impact of DAA therapy on drugs metabolized by the liver The pharmacokinetics of drugs that are metabolized by the liver (e.g. immunosuppressive agents such as calcineurin inhibitors) may be impacted by changes in liver function during DAA therapy, related to clearance of HCV. Other interactions Drug interaction information for SOVIRA with potential concomitant medicinal products is summarised in Table 5 below (where 90% confidence interval (CI) of the geometric leastsquares mean (GLSM) ratio were within &ldquo;&harr;&rdquo;, extended above &ldquo;&uarr;&rdquo;, or extended below &ldquo;&darr;&rdquo; the predetermined equivalence boundaries). The table is not all-inclusive.</p><p><strong>Table5 :Interactions between SOVIRA and other medicinal products</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:265px"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="vertical-align:top; width:262px"><p><strong>Effects on drug levels.</strong></p><p><strong>Mean ratio (90% confidence interval) for AUC, C</strong><strong>m</strong><strong>a</strong><strong>x </strong><strong>, C</strong><strong>m</strong><strong>i</strong><strong>n </strong><strong>a</strong><strong>,b</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Recommendation concerning co-administration with</strong></p><p><strong>SOVIRA</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ANALEPTICS</strong></p></td></tr><tr><td style="vertical-align:top; width:265px"><p>Modafinil</p></td><td style="vertical-align:top; width:262px"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Sofosbuvir</p><p>&harr; GS-331007</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top"><p>Co-administration of SOVIRA with modafinil is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVIRA. Such co-administration is not recommended</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ANTIARRHYTHMICS</strong></p></td></tr><tr><td style="vertical-align:top; width:265px"><p>Amiodarone</p></td><td style="vertical-align:top; width:262px"><p>Interaction not studied.</p></td><td colspan="2" style="vertical-align:top"><p>Use only if no other alternative is available. Close monitoring is recommended if this medicinal product is administered with SOVIRA (see sections 4.4 and 4.8).</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ANTICOAGULANTS</strong></p></td></tr><tr><td style="vertical-align:top; width:265px"><p>Vitamin K antagonists</p></td><td style="vertical-align:top; width:262px"><p>Interaction not studied</p></td><td colspan="2" style="vertical-align:top"><p>Close monitoring of INR is recommended with all vitamin K antagonists. This is due to liver function changes during treatment with SOVIRA.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ANTICONVULSANTS</strong></p></td></tr><tr><td style="vertical-align:top; width:265px"><p>Phenobarbital</p><p>Phenytoin</p></td><td style="vertical-align:top; width:262px"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; Sofosbuvir</p><p>&harr; GS-331007</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top"><p>SOVIRA is contraindicated with phenobarbital and phenytoin (see section 4.3).</p></td></tr><tr><td style="vertical-align:top; width:265px">Carbamazepine</td><td style="vertical-align:top; width:262px"><p>Sofosbuvir</p><p>&darr; Cmax 0.52 (0.43, 0.62)</p><p>&darr; AUC 0.52 (0.46, 0.59)</p><p>Cmin (NA)</p><p>GS 331007</p><p>&harr; Cmax 1.04 (0.97, 1.11)</p><p>&harr; AUC 0.99 (0.94, 1.04)</p><p>Cmin (NA)</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top">SOVIRA is contraindicated with carbamazepine (see section 4.3).</td></tr><tr><td style="vertical-align:top; width:265px">Oxcarbazepine</td><td style="vertical-align:top; width:262px"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; Sofosbuvir</p><p>&harr; GS-331007</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top">Co-administration of SOVIRA with oxcarbazepine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVIRA. Such coadministration is not recommended (see section 4.4).</td></tr><tr><td colspan="4" style="vertical-align:top"><strong>ANTIMYCOBACTERIALS</strong></td></tr><tr><td style="vertical-align:top; width:265px">Rifampicinf (600 mg single dose)</td><td style="vertical-align:top; width:262px"><p>Sofosbuvir</p><p>&darr; Cmax 0.23 (0.19, 0.29)</p><p>&darr; AUC 0.28 (0.24, 0.32)</p><p>Cmin (NA)</p><p>GS-331007</p><p>&harr; Cmax 1.23 (1.14, 1.34)</p><p>&harr; AUC 0.95 (0.88, 1.03)</p><p>Cmin (NA)</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top">SOVIRA is contraindicated with rifampicin (see section 4.3).</td></tr><tr><td style="vertical-align:top; width:265px">Rifabutin</td><td style="vertical-align:top; width:262px"><p>Sofosbuvir</p><p>&darr; Cmax 0.64 (0.53, 0.77)</p><p>&darr; AUC 0.76 (0.63, 0.91)</p><p>Cmin (NA)</p><p>GS 331007</p><p>&harr; Cmax 1.15 (1.03, 1.27)</p><p>&harr; AUC 1.03 (0.95, 1.12)</p><p>Cmin (NA)</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of SOVIRA is required when concomitantly used with rifabutin.</td></tr><tr><td style="vertical-align:top; width:265px">Rifapentine</td><td style="vertical-align:top; width:262px"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; Sofosbuvir</p><p>&harr; GS-331007</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top">Co-administration of SOVIRA with rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVIRA. Such co-administration is not recommended (see section 4.4).</td></tr><tr><td colspan="4" style="vertical-align:top"><strong>HERBAL SUPPLEMENTS</strong></td></tr><tr><td style="vertical-align:top; width:265px">St. John&#39;s wort</td><td style="vertical-align:top; width:262px"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; Sofosbuvir</p><p>&harr; GS-331007</p><p>(Induction of P-gp)</p></td><td colspan="2" style="vertical-align:top">SOVIRA is contraindicated with St. John&#39;s wort (see section 4.3).</td></tr><tr><td colspan="4" style="vertical-align:top"><strong>HCV ANITIVIRAL AGENTS: HCV PROTEASE INHIBITORS</strong></td></tr><tr><td style="vertical-align:top; width:265px">Boceprevir (BOC) Telaprevir (TPV)</td><td style="vertical-align:top; width:262px"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; Sofosbuvir (TPV)</p><p>&harr; Sofosbuvir (BOC)</p><p>&harr; GS-331007 (TPV or BOC)</p></td><td colspan="2" style="vertical-align:top">No drug-drug interaction data exists regarding the co-administration of SOVIRA with boceprevir or telaprevir.</td></tr><tr><td colspan="4" style="vertical-align:top">NARCOTIC ANALGESICS</td></tr><tr><td style="vertical-align:top; width:265px">Methadonef (Methadone maintenance therapy [30 to 130 mg/daily])</td><td style="vertical-align:top; width:262px"><p>R-methadone</p><p>&harr; Cmax 0.99 (0.85, 1.16)</p><p>&harr; AUC 1.01 (0.85, 1.21)</p><p>&harr; Cmin 0.94 (0.77, 1.14)</p><p>S-methadone</p><p>&harr; Cmax 0.95 (0.79, 1.13)</p><p>&harr; AUC 0.95 (0.77, 1.17)</p><p>&harr; Cmin 0.95 (0.74, 1.22)</p><p>Sofosbuvir</p><p>&darr; Cmax 0.95c (0.68, 1.33)</p><p>&uarr; AUC 1.30c (1.00, 1.69)</p><p>Cmin (NA) GS-331007</p><p>&darr; Cmax 0.73c (0.65, 0.83)</p><p>&harr; AUC 1.04c (0.89, 1.22)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or methadone is required when sofosbuvir and methadone are used concomitantly.</td></tr><tr><td colspan="4" style="vertical-align:top"><strong>IMMUNOSUPPRESSANTS</strong></td></tr><tr><td style="vertical-align:top; width:265px"><p>Ciclosporine</p><p>(600 mg single dose)</p></td><td style="vertical-align:top; width:262px"><p>Ciclosporin</p><p>&harr; Cmax 1.06 (0.94, 1.18)</p><p>&harr; AUC 0.98 (0.85, 1.14)</p><p>Cmin (NA) Sofosbuvir</p><p>&uarr; Cmax 2.54 (1.87, 3.45)</p><p>&uarr; AUC 4.53 (3.26, 6.30)</p><p>Cmin (NA) GS-331007</p><p>&darr; Cmax 0.60 (0.53, 0.69)</p><p>&harr; AUC 1.04 (0.90, 1.20)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or ciclosporin is required at initiation of co-administration. Afterwards, close monitoring and potential dose adjustment of ciclosporin may be required.</td></tr><tr><td style="vertical-align:top; width:265px">Tacrolimuse (5 mg single dose)</td><td style="vertical-align:top; width:262px"><p>Tacrolimus</p><p>&darr; Cmax 0.73 (0.59, 0.90)</p><p>&harr; AUC 1.09 (0.84, 1.40)</p><p>Cmin (NA)</p><p>Sofosbuvir</p><p>&darr; Cmax 0.97 (0.65, 1.43)</p><p>&uarr; AUC 1.13 (0.81, 1.57)</p><p>Cmin (NA) GS-331007</p><p>&harr; Cmax 0.97 (0.83, 1.14)</p><p>&harr; AUC 1.00 (0.87, 1.13)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or tacrolimus is required at initiation of co-administration. Afterwards, close monitoring and potential dose adjustment of tacrolimus may be required.</td></tr><tr><td colspan="4" style="vertical-align:top"><strong>HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS</strong></td></tr><tr><td style="vertical-align:top; width:265px">Efavirenzf (600 mg once daily)d</td><td style="vertical-align:top; width:262px"><p>Efavirenz</p><p>&harr; Cmax 0.95 (0.85, 1.06)</p><p>&harr; AUC 0.96 (0.91, 1.03)</p><p>&harr; Cmin 0.96 (0.93, 0.98)</p><p>Sofosbuvir</p><p>&darr; Cmax 0.81 (0.60, 1.10)</p><p>&harr; AUC 0.94 (0.76, 1.16)</p><p>Cmin (NA) GS-331007</p><p>&darr; Cmax 0.77 (0.70, 0.84)</p><p>&harr; AUC 0.84 (0.76, 0.92)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or efavirenz is required when sofosbuvir and efavirenz are used concomitantly.</td></tr><tr><td style="vertical-align:top; width:265px">Emtricitabinef (200 mg once daily)d</td><td style="vertical-align:top; width:262px"><p>Emtricitabine</p><p>&harr; Cmax 0.97 (0.88, 1.07)</p><p>&harr; AUC 0.99 (0.94, 1.05)</p><p>&harr; Cmin 1.04 (0.98, 1.11)</p><p>Sofosbuvir</p><p>&darr; Cmax 0.81 (0.60, 1.10)</p><p>&harr; AUC 0.94 (0.76, 1.16)</p><p>Cmin (NA) GS-331007</p><p>&darr; Cmax 0.77 (0.70, 0.84)</p><p>&harr; AUC 0.84 (0.76, 0.92) Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or emtricitabine is required when sofosbuvir and emtricitabine are used concomitantly</td></tr><tr><td style="vertical-align:top; width:265px">Tenofovir disoproxilf (245 mg once daily)d</td><td style="vertical-align:top; width:262px"><p>Tenofovir</p><p>&uarr; Cmax 1.25 (1.08, 1.45)</p><p>&harr; AUC 0.98 (0.91, 1.05)</p><p>&harr; Cmin 0.99 (0.91, 1.07) Sofosbuvir</p><p>&darr; Cmax 0.81 (0.60, 1.10)</p><p>&harr; AUC 0.94 (0.76, 1.16)</p><p>Cmin (NA) GS-331007</p><p>&darr; Cmax 0.77 (0.70, 0.84)</p><p>&harr; AUC 0.84 (0.76, 0.92)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or tenofovir disoproxil is required when sofosbuvir and tenofovir disoproxil are used concomitantly.</td></tr><tr><td style="vertical-align:top; width:265px">Rilpivirinef (25 mg once daily)</td><td style="vertical-align:top; width:262px"><p>Rilpivirine</p><p>&harr; Cmax 1.05 (0.97, 1.15)</p><p>&harr; AUC 1.06 (1.02, 1.09)</p><p>&harr; Cmin 0.99 (0.94, 1.04)</p><p>Sofosbuvir</p><p>&uarr; Cmax 1.21 (0.90, 1.62)</p><p>&harr; AUC 1.09 (0.94, 1.27)</p><p>Cmin (NA) GS-331007</p><p>&harr; Cmax 1.06 (0.99, 1.14)</p><p>&harr; AUC 1.01 (0.97, 1.04)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or rilpivirine is required when sofosbuvir and rilpivirine are used concomitantly.</td></tr><tr><td colspan="4" style="vertical-align:top; width:265px"><strong>HIV ANTIVIRAL AGENTS: HIV PROTEASE INHIBITORS</strong></td></tr><tr><td style="vertical-align:top; width:265px">Darunavir boosted with ritonavirf (800/100 mg once daily)</td><td style="vertical-align:top; width:262px"><p>Darunavir</p><p>&harr; Cmax 0.97 (0.94, 1.01)</p><p>&harr; AUC 0.97 (0.94, 1.00)</p><p>&harr; Cmin 0.86 (0.78, 0.96)</p><p>Sofosbuvir</p><p>&uarr; Cmax 1.45 (1.10, 1.92)</p><p>&uarr; AUC 1.34 (1.12, 1.59)</p><p>Cmin (NA)</p><p>GS-331007</p><p>&harr; Cmax 0.97 (0.90, 1.05)</p><p>&harr; AUC 1.24 (1.18, 1.30)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or darunavir (ritonavir boosted) is required when sofosbuvir and darunavir are used concomitantly</td></tr><tr><td colspan="4" style="vertical-align:top; width:265px">HIV ANTIVIRAL AGENTS: INTEGRASE INHIBITORS</td></tr><tr><td style="vertical-align:top; width:265px">Raltegravirf (400 mg twice daily)</td><td style="vertical-align:top; width:262px"><p>Raltegravir</p><p>&darr; Cmax 0.57 (0.44, 0.75)</p><p>&darr; AUC 0.73 (0.59, 0.91)</p><p>&harr; Cmin 0.95 (0.81, 1.12)</p><p>Sofosbuvir</p><p>&harr; Cmax 0.87 (0.71, 1.08)</p><p>&harr; AUC 0.95 (0.82, 1.09)</p><p>Cmin (NA)</p><p>GS-331007</p><p>&harr; Cmax 1.09 (0.99, 1.20)</p><p>&harr; AUC 1.03 (0.97, 1.08)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of sofosbuvir or raltegravir is required when sofosbuvir and raltegravir are used concomitantly.</td></tr><tr><td colspan="4" style="vertical-align:top; width:265px"><strong>ORAL CONTRACEPTIVES</strong></td></tr><tr><td style="vertical-align:top; width:265px">Norgestimate/ethinyl estradiol</td><td style="vertical-align:top; width:262px"><p>Norgestromin</p><p>&harr; Cmax 1.06 (0.93, 1.22)</p><p>&harr; AUC 1.05 (0.92, 1.20)</p><p>Cmin (NA)</p><p>Norgestrel</p><p>&harr; Cmax 1.18 (0.99, 1.41)</p><p>&harr; AUC 1.19 (0.98, 1.44)</p><p>Cmin (NA)</p><p>Ethinyl estradiol</p><p>&harr; Cmax 1.14 (0.96, 1.36)</p><p>&harr; AUC 1.08 (0.93, 1.25)</p><p>Cmin (NA)</p></td><td colspan="2" style="vertical-align:top">No dose adjustment of norgestimate/ethinyl estradiol is required when sofosbuvir and norgestimate/ethinyl estradiol are used concomitantly.</td></tr></tbody></table><p>NA = not available/not applicable</p><p>a. Mean ratio (90% CI) of co-administered drug pharmacokinetics with/without sofosbuvir and mean ratio of sofosbuvir and GS-331007 with/without co-administered drug. No effect = 1.00</p><p>b. All interaction studies conducted in healthy volunteers</p><p>c. Comparison based on historical control</p><p>d. Administered as Atripla</p><p>e. Bioequivalence boundary 80%-125%</p><p>f. Equivalence boundary 70%-143%</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential / contraception in males and females When SOVIRA is used in combination with ribavirin or peginterferon alfa/ribavirin, extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin (see section 4.4). Women of childbearing potential or their male partners must use an effective form of contraception during treatment and for a period of time after the treatment has concluded as recommended in the Summary of Product Characteristics for ribavirin. Refer to the Summary of Product Characteristics for ribavirin for additional information. Pregnancy There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of sofosbuvir in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. No effects on foetal development have been observed in rats and rabbits at the highest doses tested. However, it has not been possible to fully estimate exposure margins achieved for sofosbuvir in the rat relative to the exposure in humans at the recommended clinical dose (see section 5.3). As a precautionary measure, it is preferable to avoid the use of SOVIRA during pregnancy. However, if ribavirin is co-administered with sofosbuvir, the contraindications regarding use of ribavirin during pregnancy apply (see also the Summary of Product Characteristics for ribavirin). Breast-feeding It is unknown whether sofosbuvir and its metabolites are excreted in human milk.Available pharmacokinetic data in animals have shown excretion of metabolites in milk (for details see section 5.3). A risk to newborns/infants cannot be excluded. Therefore, SOVIRA should not be used during breast-feeding. Fertility No human data on the effect of SOVIRA on fertility are available. Animal studies do not indicate harmful effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SOVIRA has moderate influence on the ability to drive and use machines. Patients should be informed that fatigue and disturbance in attention, dizziness and blurred vision have been reported during treatment with sofosbuvir in combination with peginterferon alfa and ribavirin (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile in adults Assessment of adverse reactions is based on pooled data from five Phase 3 clinical studies (both controlled and uncontrolled). SOVIRA has been studied in combination with ribavirin, with or without peginterferon alfa. In this context, no adverse drug reactions specific to sofosbuvir have been identified. The most common adverse drug reactions occurring in patients receiving sofosbuvir and ribavirin or sofosbuvir, ribavirin and peginterferon alfa were fatigue, headache, nausea and insomnia. Tabulated summary of adverse reactions The following adverse drug reactions have been identified with sofosbuvir in combination with ribavirin or in combination with peginterferon alfa and ribavirin (Table 6). The adverse reactions are listed below by body system organ class and frequency. Frequencies are defined as follows: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) or very rare (&lt;1/10,000).</p><p><strong>Table 4: Adverse drug reactions identified with sofosbuvir in combination with ribavirin or peginterferon alfa and ribavirin</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>SOF</strong><strong>a </strong><strong>+ RBV</strong><strong>b</strong></p></td><td style="vertical-align:top"><p><strong>SOF + PEG</strong><strong>c </strong><strong>+ RBV</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Infections and infestations:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>nasopharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Blood and lymphatic system disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>haemoglobin decreased</p></td><td style="vertical-align:top"><p>anaemia, neutropenia, lymphocyte count decreased, platelet count decreased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Metabolism and nutrition disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>weight decreased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Psychiatric disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>depression</p></td><td style="vertical-align:top"><p>depression, anxiety, agitation</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nervous system disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>dizziness, headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>disturbance in attention</p></td><td style="vertical-align:top"><p>migraine, memory impairment, disturbance in attention</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><em>Eye disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vision blurred</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dyspnoea, cough</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>dyspnoea, dyspnoea exertional, cough</p></td><td style="vertical-align:top"><p>dyspnoea exertional</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Gastrointestinal disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>diarrhoea, nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>abdominal discomfort, constipation, dyspepsia</p></td><td style="vertical-align:top"><p>constipation, dry mouth, gastroesophageal reflux</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Hepatobiliary disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>blood bilirubin increased</p></td><td style="vertical-align:top"><p>blood bilirubin increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>S</em><em>kin and subcutaneous tissue disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>alopecia, dry skin, pruritus</p></td><td style="vertical-align:top"><p>alopecia, dry skin</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>arthralgia, back pain, muscle spasms, myalgia</p></td><td style="vertical-align:top"><p>back pain, muscle spasms</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>General disorders and administration site conditions:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>fatigue, irritability</p></td><td style="vertical-align:top"><p>chills, fatigue, influenza-like illness, irritability, pain, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>pyrexia, asthenia</p></td><td style="vertical-align:top"><p>chest pain, asthenia</p></td></tr></tbody></table><p>a. SOF = sofosbuvir; b. RBV = ribavirin; c. PEG = peginterferon alfa.</p><p>&nbsp;</p><p>Description of selected adverse reactions Cardiac arrhythmias Cases of severe bradycardia and heart block have been observed when sofosbuvir containingregimes are used in combination with amiodarone and/or other medicinal products that lower heart rate (see sections 4.4 and 4.5). Skin disorders Frequency not known: Stevens-Johnson syndrome</p><p>Other special population(s) HIV/HCV co-infection The safety profile of sofosbuvir and ribavirin in HCV/HIV co-infected adult patients was similar to that observed in mono-infected HCV patients treated with sofosbuvir and ribavirin in Phase 3 clinical studies (see section 5.1). Patients awaiting liver transplantation The safety profile of sofosbuvir and ribavirin in HCV infected adult patients prior to liver transplantation was similar to that observed in patients treated with sofosbuvir and ribavirin in Phase 3 clinical studies (see section 5.1). Patients with Renal Impairment Sofosbuvir in a fixed dose combination with ledipasvir was administered for 12 weeks to 18 patients with genotype 1 CHC and severe renal impairment in an open-label study (Study 0154). The safety of sofosbuvir in a fixed dose combination with either ledipasvir or velpatasvir has been studied in 154 patients with ESRD requiring dialysis (Study 4062 and Study 4063). In this setting, exposure of sofosbuvir metabolite GS-331007 is 20-fold increased, exceeding levels where adverse reactions have been observed in preclinical trials. In this limited clinical safety data set, the rate of adverse events and deaths was not clearly elevated from what is expected in ESRD patients. Liver transplant recipients The safety profile of sofosbuvir and ribavirin in liver transplant adult recipients with chronic hepatitis C was similar to that observed in patients treated with sofosbuvir and ribavirin in Phase 3 clinical studies (see section 5.1). In study 0126, decreases in haemoglobin during treatment were very common with 32.5% (13/40 patients) experiencing a decline in haemoglobin to &lt;10 g/dL, 1 of whom also had a decline to &lt;8.5 g/dL. Eight patients (20%) received epoetin and/or a blood product. In 5 patients (12.5%), study drugs were discontinued, modified or interrupted due to adverse events. Paediatric population The safety and efficacy of SOVIRA in adolescents aged 12 to &lt;18 years are based on data from 50 patients who were treated with SOVIRA and ribavirin for 12 weeks (genotype 2 patients) and 24 weeks (genotype 3 patients) in a Phase 2, open-label clinical trial. The adverse reactions observed were consistent with those observed in clinical studies of SOVIRA plus ribavirin in adults (see Table 6)</p><p>Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>To report any side effect(s):</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Reporting hotline: 19999.</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest documented dose of sofosbuvir was a single supratherapeutic dose of sofosbuvir 1,200 mg administered to 59 healthy subjects. In that study, there were no untoward effects observed at this dose level, and adverse reactions were similar in frequency and severity to those reported in the placebo and sofosbuvir 400 mg treatment groups. The effects of higher doses are unknown.</p><p>No specific antidote is available for overdose with SOVIRA. If overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose with SOVIRA consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. Haemodialysis can efficiently remove (53% extraction ratio) the predominant circulating metabolite GS-331007. A 4-hour haemodialysis session removed 18% of the administered dose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, direct-acting antiviral; ATC code: J05AP08</p><p><u>Mechanism of action </u></p><p>Sofosbuvir is a pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. In a biochemical assay, GS-461203 inhibited the polymerase activity of the recombinant NS5B from HCV genotype 1b, 2a, 3a and 4a with a 50% inhibitory concentration (IC50) value ranging from 0.7 to 2.6 &mu;M. GS-461203 (the active metabolite of sofosbuvir) is not an inhibitor of human DNA and RNA polymerases nor an inhibitor of mitochondrial RNA polymerase.</p><p><u>Antiviral activity </u></p><p>In HCV replicon assays, the effective concentration (EC50) values of sofosbuvir against full-length replicons from genotype 1a, 1b, 2a, 3a and 4a were 0.04, 0.11, 0.05, 0.05 and 0.04 &mu;M, respectively, and EC50 values of sofosbuvir against chimeric 1b replicons encoding NS5B from genotype 2b, 5a or 6a were 0.014 to 0.015 &mu;M. The mean &plusmn; SD EC50 of sofosbuvir against chimeric replicons encoding NS5B sequences from clinical isolates was 0.068 &plusmn; 0.024 &mu;M for genotype 1a (n = 67), 0.11 &plusmn; 0.029 &mu;M for genotype 1b (n = 29), 0.035 &plusmn; 0.018 &mu;M for genotype 2 (n = 15) and 0.085 &plusmn; 0.034 &mu;M for genotype 3a (n = 106). In these assays, the in vitro antiviral activity of sofosbuvir against the less common genotypes 4, 5 and 6 was similar to that observed for genotypes 1, 2 and 3.</p><p>The presence of 40% human serum had no effect on the anti-HCV activity of sofosbuvir.</p><p><u>Resistance </u></p><p><em>In cell culture </em></p><p>HCV replicons with reduced susceptibility to sofosbuvir have been selected in cell culture for multiple genotypes including 1b, 2a, 2b, 3a, 4a, 5a and 6a. Reduced susceptibility to sofosbuvir was associated with the primary NS5B substitution S282T in all replicon genotypes examined. Site-directed mutagenesis of the S282T substitution in replicons of 8 genotypes conferred 2- to 18-fold reduced susceptibility to sofosbuvir and reduced the replication viral capacity by 89% to 99% compared to the corresponding wild-type. In biochemical assays, recombinant NS5B polymerase from genotypes 1b, 2a, 3a and 4a expressing the S282T substitution showed reduced susceptibility to GS-461203 compared to respective wild-types.</p><p><em>In clinical studies - Adults </em></p><p>In a pooled analysis of 991 patients who received sofosbuvir in Phase 3 studies, 226 patients qualified for resistance analysis due to virologic failure or early study drug discontinuation and having HCV RNA &gt;1,000 IU/mL. Post-baseline NS5B sequences were available for 225 of the 226 patients, with deep sequencing data (assay cutoff of 1%) from 221 of these patients. The sofosbuvir-associated resistance substitution S282T was not detected in any of these patients by deep sequencing or population sequencing. The S282T substitution in NS5B was detected in a single subject receiving SOVIRA monotherapy in a Phase 2 study. This subject harboured &lt;1% HCV S282T at baseline and developed S282T (&gt;99%) at 4 weeks post-treatment which resulted in a 13.5-fold change in sofosbuvir EC50 and reduced viral replication capacity. The S282T substitution reverted to wild-type over the next 8 weeks and was no longer detectable by deep sequencing at 12 weeks post-treatment.</p><p>Two NS5B substitutions, L159F and V321A, were detected in post-treatment relapse samples from multiple genotype 3 HCV infected patients in the Phase 3 clinical studies. No shift in the phenotypic susceptibility to sofosbuvir or ribavirin of subject isolates with these substitutions was detected. In addition, S282R and L320F substitutions were detected on treatment by deep sequencing in a pre-transplant subject with a partial treatment response. The clinical significance of these findings is unknown.</p><p><u>Effect of baseline HCV polymorphisms on treatment outcome </u></p><p><em>Adult population </em></p><p>Baseline NS5B sequences were obtained for 1,292 patients from Phase 3 studies by population sequencing and the S282T substitution was not detected in any subject with available baseline sequence. In an analysis evaluating the effect of baseline polymorphisms on treatment outcome, no statistically significant association was observed between the presence of any HCV NS5B variant at baseline and treatment outcome.</p><p><em>Paediatric population </em></p><p>Baseline NS5B sequences were obtained for 47 patients in the Phase 2 study. Among these, one patient was found to have a NS5B RAV substitution (F289L). This patient achieved SVR12.</p><p><u>Cross-resistance </u></p><p>HCV replicons expressing the sofosbuvir-associated resistance substitution S282T were fully susceptible to other classes of anti-HCV agents. Sofosbuvir retained activity against the NS5B substitutions L159F and L320F associated with resistance to other nucleoside inhibitors. Sofosbuvir was fully active against substitutions associated with resistance to other direct-acting antivirals with different mechanisms of actions, such as NS5B non-nucleoside inhibitors, NS3 protease inhibitors and NS5A inhibitors.</p><p><u>Clinical efficacy and safety </u></p><p>The efficacy of sofosbuvir was evaluated in five Phase 3 studies in a total of 1,568 adult patients with genotypes 1 to 6 chronic hepatitis C. One study was conducted in treatment-na&iuml;ve patients with genotype 1, 4, 5 or 6 chronic hepatitis C in combination with peginterferon alfa 2a and ribavirin and the other four studies were conducted in patients with genotype 2 or 3 chronic hepatitis C in combination with ribavirin including one in treatment-na&iuml;ve patients, one in interferon intolerant, ineligible or unwilling patients, one in patients previously treated with an interferon-based regimen, and one in all patients irrespective of prior treatment history or ability to receive treatment with interferon. Patients in these studies had compensated liver disease including cirrhosis. Sofosbuvir was administered at a dose of 400 mg once daily. The ribavirin dose was weight-based at 1,000-1,200 mg daily administered in two divided doses, and the peginterferon alfa 2a dose, where applicable, was 180 &mu;g per week. Treatment duration was fixed in each study and was not guided by patients&#39; HCV RNA levels (no response guided algorithm).</p><p>Plasma HCV RNA values were measured during the clinical studies using the COBAS TaqMan HCV test (version 2.0), for use with the High Pure System. The assay had a lower limit of quantification (LLOQ) of 25 IU/mL. Sustained virologic response (SVR) was the primary endpoint to determine the HCV cure rate for all studies which was defined as HCV RNA less than LLOQ at 12 weeks after the end of treatment (SVR12).</p><p><em><u>Clinical studies in patients with genotype 1, 4, 5 and 6 chronic hepatitis C </u></em></p><p><em>Treatment-na&iuml;ve adult patients - NEUTRINO (study 110) </em></p><p>NEUTRINO was an open-label, single-arm study that evaluated 12 weeks of treatment with sofosbuvir in combination with peginterferon alfa 2a and ribavirin in treatment-na&iuml;ve patients with genotype 1, 4, 5 or 6 HCV infection.</p><p>Treated patients (n = 327) had a median age of 54 years (range: 19 to 70); 64% of the patients were male; 79% were White; 17% were Black; 14% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 18 to 56 kg/m2); 78% had baseline HCV RNA greater than 6 log10 IU/mL; 17% had cirrhosis; 89% had HCV genotype 1 and 11% had HCV genotype 4, 5 or 6. Table 7 presents the response rates for the treatment group of sofosbuvir + peginterferon alfa + ribavirin.</p><p><strong>Table 7: Response rates in study NEUTRINO </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>SOF+PEG+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 327) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall SVR12</p></td><td style="vertical-align:top"><p>91% (296/327)</p></td></tr><tr><td style="vertical-align:top"><p>Outcome for patients without SVR12</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>On-treatment virologic failure</p></td><td style="vertical-align:top"><p>0/327</p></td></tr><tr><td style="vertical-align:top"><p>Relapse<sup>a</sup></p></td><td style="vertical-align:top"><p>9% (28/326)</p></td></tr><tr><td style="vertical-align:top"><p>Other<sup>b</sup></p></td><td style="vertical-align:top"><p>1% (3/327)</p></td></tr></tbody></table><p>a. The denominator for relapse is the number of patients with HCV RNA &lt;LLOQ at their last on-treatment assessment.</p><p>b. Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</p><p>Response rates for selected subgroups are presented in Table 8.</p><p><strong>Table 8: SVR12 rates for selected subgroups in NEUTRINO </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>SOF+PEG+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 327) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Genotype</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Genotype 1</p></td><td style="vertical-align:top"><p>90% (262/292)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 4, 5 or 6</p></td><td style="vertical-align:top"><p>97% (34/35)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>93% (253/273)</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>80% (43/54)</p></td></tr><tr><td style="vertical-align:top"><p>Race</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Black</p></td><td style="vertical-align:top"><p>87% (47/54)</p></td></tr><tr><td style="vertical-align:top"><p>Non-Black</p></td><td style="vertical-align:top"><p>91% (249/273)</p></td></tr></tbody></table><p>SVR12 rates were similarly high in patients with baseline IL28B C/C allele [94/95 (99%)] and non-C/C (C/T or T/T) allele [202/232 (87%)].</p><p>27/28 patients with genotype 4 HCV achieved SVR12. A single subject with genotype 5 and all 6 patients with genotype 6 HCV infection in this study achieved SVR12.</p><p><em><u>Clinical studies in patients with genotype 2 and 3 chronic hepatitis C </u></em></p><p><em>Treatment-na&iuml;ve adults - FISSION (study 1231) </em></p><p>FISSION was a randomised, open-label, active-controlled study that evaluated 12 weeks of treatment with sofosbuvir and ribavirin compared to 24 weeks of treatment with peginterferon alfa 2a and ribavirin in treatment-na&iuml;ve patients with genotype 2 or 3 HCV infection. The ribavirin doses used in the sofosbuvir + ribavirin and peginterferon alfa 2a + ribavirin arms were weight-based 1,000-1,200 mg/day and 800 mg/day regardless of weight, respectively. Patients were randomised in a 1:1 ratio and stratified by cirrhosis (presence versus absence), HCV genotype (2 versus 3) and baseline HCV RNA level (&lt;6 log10 IU/mL versus &ge;6 log10 IU/mL). Patients with genotype 2 or 3 HCV were enrolled in an approximately 1:3 ratio.</p><p>Treated patients (n = 499) had a median age of 50 years (range: 19 to 77); 66% of the patients were male; 87% were White; 3% were Black; 14% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 17 to 52 kg/m2); 57% had baseline HCV RNA levels greater than 6 log10 IU/mL; 20% had cirrhosis; 72% had HCV genotype 3. Table 9 presents the response rates for the treatment groups of sofosbuvir + ribavirin and peginterferon alfa + ribavirin.</p><p><strong>Table 9: Response rates in study FISSION </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 256)<sup>a </sup></strong></p></td><td style="vertical-align:top"><p><strong>PEG+RBV </strong></p><p><strong>24 weeks </strong></p><p><strong>(n = 243) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall SVR12</p></td><td style="vertical-align:top"><p>67% (171/256)</p></td><td style="vertical-align:top"><p>67% (162/243)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 2</p></td><td style="vertical-align:top"><p>95% (69/73)</p></td><td style="vertical-align:top"><p>78% (52/67)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 3</p></td><td style="vertical-align:top"><p>56% (102/183)</p></td><td style="vertical-align:top"><p>63% (110/176)</p></td></tr><tr><td style="vertical-align:top"><p>Outcome for patients without SVR12</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>On-treatment virologic failure</p></td><td style="vertical-align:top"><p>&lt; 1% (1/256)</p></td><td style="vertical-align:top"><p>7% (18/243)</p></td></tr><tr><td style="vertical-align:top"><p>Relapse<sup>b</sup></p></td><td style="vertical-align:top"><p>30% (76/252)</p></td><td style="vertical-align:top"><p>21% (46/217)</p></td></tr><tr><td style="vertical-align:top"><p>Other<sup>c</sup></p></td><td style="vertical-align:top"><p>3% (8/256)</p></td><td style="vertical-align:top"><p>7% (17/243)</p></td></tr></tbody></table><p>a. The efficacy analysis includes 3 patients with recombinant genotype 2/1 HCV infection.</p><p>b. The denominator for relapse is the number of patients with HCV RNA &lt;LLOQ at their last on-treatment assessment.</p><p>c. Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</p><p>The difference in the overall SVR12 rates between sofosbuvir + ribavirin and peginterferon alfa + ribavirin treatment groups was 0.3% (95% confidence interval: -7.5% to 8.0%) and the study met the predefined non-inferiority criterion.</p><p>Response rates for patients with cirrhosis at baseline are presented in Table 10 by HCV genotype.</p><p><strong>Table 10: SVR12 rates by cirrhosis and genotype in study FISSION </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>Genotype 2 </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Genotype 3 </strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 73)<sup>a</sup> </strong></p></td><td style="vertical-align:top"><p><strong>PEG+RBV </strong></p><p><strong>24 weeks </strong></p><p><strong>(n = 67) </strong></p></td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 183) </strong></p></td><td style="vertical-align:top"><p><strong>PEG+RBV </strong></p><p><strong>24 weeks </strong></p><p><strong>(n = 176) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>97% (59/61)</p></td><td style="vertical-align:top"><p>81% (44/54)</p></td><td style="vertical-align:top"><p>61% (89/145)</p></td><td style="vertical-align:top"><p>71% (99/139)</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>83% (10/12)</p></td><td style="vertical-align:top"><p>62% (8/13)</p></td><td style="vertical-align:top"><p>34% (13/38)</p></td><td style="vertical-align:top"><p>30% (11/37)</p></td></tr></tbody></table><p>a. The efficacy analysis includes 3 patients with recombinant genotype 2/1 HCV infection.</p><p>Interferon intolerant, ineligible or unwilling adults - POSITRON (study 107)</p><p>POSITRON was a randomised, double-blinded, placebo-controlled study that evaluated 12 weeks of treatment with sofosbuvir and ribavirin (n = 207) compared to placebo (n = 71) in patients who are interferon intolerant, ineligible or unwilling. Patients were randomised in 3:1 ratio and stratified by cirrhosis (presence versus absence).</p><p>Treated patients (n = 278) had a median age of 54 years (range: 21 to 75); 54% of the patients were male; 91% were White; 5% were Black; 11% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 18 to 53 kg/m2); 70% had baseline HCV RNA levels greater than 6 log10 IU/mL; 16% had cirrhosis; 49% had HCV genotype 3. The proportions of patients who were interferon intolerant, ineligible, or unwilling were 9%, 44%, and 47%, respectively. Most patients had no prior HCV treatment (81.3%). Table 11 presents the response rates for the treatment groups of sofosbuvir + ribavirin and placebo.</p><p><strong>Table 11: Response rates in study POSITRON </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 207) </strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 71) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall SVR12</p></td><td style="vertical-align:top"><p>78% (161/207)</p></td><td style="vertical-align:top"><p>0/71</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 2</p></td><td style="vertical-align:top"><p>93% (101/109)</p></td><td style="vertical-align:top"><p>0/34</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 3</p></td><td style="vertical-align:top"><p>61% (60/98)</p></td><td style="vertical-align:top"><p>0/37</p></td></tr><tr><td style="vertical-align:top"><p>Outcome for patients without SVR12</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>On-treatment virologic failure</p></td><td style="vertical-align:top"><p>0/207</p></td><td style="vertical-align:top"><p>97% (69/71)</p></td></tr><tr><td style="vertical-align:top"><p>Relapse<sup>a</sup></p></td><td style="vertical-align:top"><p>20% (42/205)</p></td><td style="vertical-align:top"><p>0/0</p></td></tr><tr><td style="vertical-align:top"><p>Other<sup>b</sup></p></td><td style="vertical-align:top"><p>2% (4/207)</p></td><td style="vertical-align:top"><p>3% (2/71)</p></td></tr></tbody></table><p>a. The denominator for relapse is the number of patients with HCV RNA &lt;LLOQ at their last on-treatment assessment.</p><p>b. Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</p><p>The SVR12 rate in the sofosbuvir + ribavirin treatment group was statistically significant when compared to placebo (p &lt;0.001).</p><p>Table 12 presents the subgroup analysis by genotype for cirrhosis and interferon classification.</p><p><strong>Table 12: SVR12 rates for selected subgroups by genotype in POSITRON </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Genotype 2 </strong></p><p><strong>(n = 109) </strong></p></td><td style="vertical-align:top"><p><strong>Genotype 3 </strong></p><p><strong>(n = 98) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>92% (85/92)</p></td><td style="vertical-align:top"><p>68% (57/84)</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>94% (16/17)</p></td><td style="vertical-align:top"><p>21% (3/14)</p></td></tr><tr><td style="vertical-align:top"><p>Interferon classification</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Ineligible</p></td><td style="vertical-align:top"><p>88% (36/41)</p></td><td style="vertical-align:top"><p>70% (33/47)</p></td></tr><tr><td style="vertical-align:top"><p>Intolerant</p></td><td style="vertical-align:top"><p>100% (9/9)</p></td><td style="vertical-align:top"><p>50% (4/8)</p></td></tr><tr><td style="vertical-align:top"><p>Unwilling</p></td><td style="vertical-align:top"><p>95% (56/59)</p></td><td style="vertical-align:top"><p>53% (23/43)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Previously treated adults - FUSION (study 108)</em></p><p>FUSION was a randomised, double-blinded study that evaluated 12 or 16 weeks of treatment with sofosbuvir and ribavirin in patients who did not achieve SVR with prior interferon-based treatment (relapsers and nonresponders). Patients were randomised in a 1:1 ratio and stratified by cirrhosis (presence versus absence) and HCV genotype (2 versus 3).</p><p>Treated patients (n = 201) had a median age of 56 years (range: 24 to 70); 70% of the patients were male; 87% were White; 3% were Black; 9% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 19 to 44 kg/m2); 73% had baseline HCV RNA levels greater than 6 log10 IU/mL; 34% had cirrhosis; 63% had HCV genotype 3; 75% were prior relapsers. Table 13 presents the response rates for the treatment groups of sofosbuvir + ribavirin for 12 weeks and 16 weeks.</p><p><strong>Table 13: Response rates in study FUSION </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 103)<sup>a </sup></strong></p></td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>16 weeks </strong></p><p><strong>(n = 98)<sup>a</sup> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall SVR12</p></td><td style="vertical-align:top"><p>50% (51/103)</p></td><td style="vertical-align:top"><p>71% (70/98)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 2</p></td><td style="vertical-align:top"><p>82% (32/39)</p></td><td style="vertical-align:top"><p>89% (31/35)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 3</p></td><td style="vertical-align:top"><p>30% (19/64)</p></td><td style="vertical-align:top"><p>62% (39/63)</p></td></tr><tr><td style="vertical-align:top"><p>Outcome for patients without SVR12</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>On-treatment virologic failure</p></td><td style="vertical-align:top"><p>0/103</p></td><td style="vertical-align:top"><p>0/98</p></td></tr><tr><td style="vertical-align:top"><p>Relapse<sup>b</sup></p></td><td style="vertical-align:top"><p>48% (49/103)</p></td><td style="vertical-align:top"><p>29% (28/98)</p></td></tr><tr><td style="vertical-align:top"><p>Other<sup>c</sup></p></td><td style="vertical-align:top"><p>3% (3/103)</p></td><td style="vertical-align:top"><p>0/98</p></td></tr></tbody></table><p>a. The efficacy analysis includes 6 patients with recombinant genotype 2/1 HCV infection.</p><p>b. The denominator for relapse is the number of patients with HCV RNA &lt;LLOQ at their last on-treatment assessment.</p><p>c. Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</p><p>Table 14 presents the subgroup analysis by genotype for cirrhosis and response to prior HCV treatment.</p><p><strong>Table 14: SVR12 rates for selected subgroups by genotype in study FUSION </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>Genotype 2 </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Genotype 3 </strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 39) </strong></p></td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>16 weeks </strong></p><p><strong>(n = 35) </strong></p></td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 64) </strong></p></td><td style="vertical-align:top"><p><strong>SOF+RBV </strong></p><p><strong>16 weeks </strong></p><p><strong>(n = 63) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>90% (26/29)</p></td><td style="vertical-align:top"><p>92% (24/26)</p></td><td style="vertical-align:top"><p>37% (14/38)</p></td><td style="vertical-align:top"><p>63% (25/40)</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>60% (6/10)</p></td><td style="vertical-align:top"><p>78% (7/9)</p></td><td style="vertical-align:top"><p>19% (5/26)</p></td><td style="vertical-align:top"><p>61% (14/23)</p></td></tr><tr><td style="vertical-align:top"><p>Response to prior HCV treatment</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Relapser</p></td><td style="vertical-align:top"><p>86% (25/29)</p></td><td style="vertical-align:top"><p>89% (24/27)</p></td><td style="vertical-align:top"><p>31% (15/49)</p></td><td style="vertical-align:top"><p>65% (30/46)</p></td></tr><tr><td style="vertical-align:top"><p>Nonresponder</p></td><td style="vertical-align:top"><p>70% (7/10)</p></td><td style="vertical-align:top"><p>88% (7/8)</p></td><td style="vertical-align:top"><p>27% (4/15)</p></td><td style="vertical-align:top"><p>53% (9/17)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Treatment-na&iuml;ve and previously treated adults - VALENCE (study 133) </em></p><p>VALENCE was a Phase 3 study that evaluated sofosbuvir in combination with weight-based ribavirin for the treatment of genotype 2 or 3 HCV infection in treatment-na&iuml;ve patients or patients who did not achieve SVR with prior interferon-based treatment, including patients with compensated cirrhosis. The study was designed as a direct comparison of sofosbuvir and ribavirin versus placebo for 12 weeks. However, based on emerging data, the study was unblinded and all HCV genotype 2 patients continued to receive sofosbuvir and ribavirin for 12 weeks, whilst treatment for HCV genotype 3 patients was extended to 24 weeks. Eleven HCV genotype 3 patients had already completed treatment with sofosbuvir and ribavirin for 12 weeks at the time of the amendment.</p><p>Treated patients (n = 419) had a median age of 51 years (range: 19 to 74); 60% of the patients were male; median body mass index was 25 kg/m2 (range: 17 to 44 kg/m2); the mean baseline HCV RNA level was 6.4 log10 IU/mL; 21% had cirrhosis; 78% had HCV genotype 3; 65% were prior relapsers. Table 15 presents the response rates for the treatment groups of sofosbuvir + ribavirin for 12 weeks and 24 weeks.</p><p>Placebo recipients are not included in the tables since none achieved SVR12.</p><p><strong>Table 15: Response rates in study VALENCE </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td><p><strong>Genotype 2 </strong></p><p><strong>SOF+RBV 12 weeks </strong></p><p><strong>(n = 73) </strong></p></td><td><p><strong>Genotype 3 </strong></p><p><strong>SOF+RBV 12 weeks </strong></p><p><strong>(n = 11) </strong></p></td><td><p><strong>Genotype 3 </strong></p><p><strong>SOF+RBV 24 weeks </strong></p><p><strong>(n = 250) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall SVR12</p></td><td style="vertical-align:top"><p>93% (68/73)</p></td><td style="vertical-align:top"><p>27% (3/11)</p></td><td style="vertical-align:top"><p>84% (210/250)</p></td></tr><tr><td style="vertical-align:top"><p>Outcome for patients without SVR12</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>On-treatment virologic failure</p></td><td style="vertical-align:top"><p>0% (0/73)</p></td><td style="vertical-align:top"><p>0% (0/11)</p></td><td style="vertical-align:top"><p>0.4% (1/250)</p></td></tr><tr><td><p>Relapse<sup>a</sup></p></td><td style="vertical-align:top"><p>7% (5/73)</p></td><td style="vertical-align:top"><p>55% (6/11)</p></td><td style="vertical-align:top"><p>14% (34/249)</p></td></tr><tr><td><p>Other<sup>b</sup></p></td><td style="vertical-align:top"><p>0% (0/73)</p></td><td style="vertical-align:top"><p>18% (2/11)</p></td><td style="vertical-align:top"><p>2% (5/250)</p></td></tr></tbody></table><p>a. The denominator for relapse is the number of patients with HCV RNA &lt;LLOQ at their last on-treatment assessment.</p><p>b. Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</p><p>Table 16 presents the subgroup analysis by genotype for cirrhosis and exposure to prior HCV treatment.</p><p><strong>Table 16: SVR12 rates for selected subgroups by genotype in study VALENCE </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Genotype 2 </strong></p><p><strong>SOF+RBV 12 weeks </strong></p><p><strong>(n = 73) </strong></p></td><td style="vertical-align:top"><p><strong>Genotype 3 </strong></p><p><strong>SOF+RBV 24 weeks </strong></p><p><strong>(n = 250) </strong></p></td></tr><tr><td><p>Treatment-na&iuml;ve</p></td><td style="vertical-align:top"><p>97% (31/32)</p></td><td style="vertical-align:top"><p>93% (98/105)</p></td></tr><tr><td><p>Non-cirrhotic</p></td><td style="vertical-align:top"><p>97% (29/30)</p></td><td style="vertical-align:top"><p>93% (86/92)</p></td></tr><tr><td><p>Cirrhotic</p></td><td style="vertical-align:top"><p>100% (2/2)</p></td><td style="vertical-align:top"><p>92% (12/13)</p></td></tr><tr><td><p>Treatment-experienced</p></td><td style="vertical-align:top"><p>90% (37/41)</p></td><td style="vertical-align:top"><p>77% (112/145)</p></td></tr><tr><td><p>Non-cirrhotic</p></td><td style="vertical-align:top"><p>91% (30/33)</p></td><td style="vertical-align:top"><p>85% (85/100)</p></td></tr><tr><td><p>Cirrhotic</p></td><td style="vertical-align:top"><p>88% (7/8)</p></td><td style="vertical-align:top"><p>60% (27/45)</p></td></tr></tbody></table><p>&nbsp;</p><p>SVR12 to SVR24 concordance</p><p>The concordance between SVR12 and SVR24 (SVR 24 weeks after the end of the treatment) following treatment with sofosbuvir in combination with ribavirin or ribavirin and pegylated interferon demonstrates a positive predictive value of 99% and a negative predictive value of 99%.</p><p><u>Clinical efficacy and safety in special populations </u></p><p><em>HCV/HIV co-infected adult patients - PHOTON-1 (study 123) </em></p><p>Sofosbuvir was studied in an open-label clinical study evaluating the safety and efficacy of 12 or 24 weeks of treatment with sofosbuvir and ribavirin in patients with genotype 1, 2 or 3 chronic hepatitis C co-infected with HIV-1. Genotype 2 and 3 patients were either treatment-na&iuml;ve or experienced, whereas genotype 1 patients were na&iuml;ve to prior treatment. Treatment duration was 12 weeks in treatment-na&iuml;ve patients with genotype 2 or 3 HCV infection, and 24 weeks in treatment-experienced patients with genotype 3 HCV infection, as well as patients with genotype 1 HCV infection. Patients received 400 mg sofosbuvir and weight-based ribavirin (1,000 mg for patients weighing &lt;75 kg or 1,200 mg for patients weighing &ge;75 kg). Patients were either not on antiretroviral therapy with a CD4+ cell count &gt;500 cells/mm3 or had virologically suppressed HIV-1 with a CD4+ cell count &gt;200 cells/mm3. 95% of patients received antiretroviral therapy at the time of enrolment. Preliminary SVR12 data are available for 210 patients.</p><p>Table 17 presents the response rates by genotype and exposure to prior HCV treatment.</p><p><strong>Table 17: Response rates in study PHOTON-1 </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td><p><strong>Genotype 2/3 treatment-na&iuml;ve </strong></p><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>(n = 68) </strong></p></td><td><p><strong>Genotype 2/3 treatment-experienced </strong></p><p><strong>SOF+RBV </strong></p><p><strong>24 weeks </strong></p><p><strong>(n = 28) </strong></p></td><td><p><strong>Genotype 1 treatment-na&iuml;ve </strong></p><p><strong>SOF+RBV </strong></p><p><strong>24 weeks </strong></p><p><strong>(n = 114) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall SVR12</p></td><td><p>75% (51/68)</p></td><td><p>93% (26/28)</p></td><td><p>76% (87/114)</p></td></tr><tr><td style="vertical-align:top"><p>Outcome for patients without SVR12</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>On-treatment virologic failure</p></td><td><p>1% (1/68)</p></td><td><p>0/28</p></td><td><p>1% (1/114)</p></td></tr><tr><td><p>Relapse<sup>a</sup></p></td><td><p>18% (12/67)</p></td><td><p>7% (2/28)</p></td><td><p>22% (25/113)</p></td></tr><tr><td><p>Other<sup>b</sup></p></td><td><p>6% (4/68)</p></td><td><p>0/28</p></td><td><p>1% (1/114)</p></td></tr></tbody></table><p>a. The denominator for relapse is the number of patients with HCV RNA &lt;LLOQ at their last on-treatment assessment.</p><p>b. Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).</p><p>Table 18 presents the subgroup analysis by genotype for cirrhosis.</p><p><strong>Table 18: SVR12 rates for selected subgroups by genotype in study PHOTON-1 </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2"><p><strong>HCV genotype 2 </strong></p></td><td colspan="2"><p><strong>HCV genotype 3 </strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>TN (n = 26) </strong></p></td><td><p><strong>SOF+RBV </strong></p><p><strong>24 weeks </strong></p><p><strong>TE (n = 15) </strong></p></td><td><p><strong>SOF+RBV </strong></p><p><strong>12 weeks </strong></p><p><strong>TN (n = 42) </strong></p></td><td><p><strong>SOF+RBV </strong></p><p><strong>24 weeks </strong></p><p><strong>TE (n = 13) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall</p></td><td><p>88% (23/26)</p></td><td><p>93% (14/15)</p></td><td><p>67% (28/42)</p></td><td><p>92% (12/13)</p></td></tr><tr><td><p>No cirrhosis</p></td><td><p>88% (22/25)</p></td><td><p>92% (12/13)</p></td><td><p>67% (24/36)</p></td><td><p>100% (8/8)</p></td></tr><tr><td><p>Cirrhosis</p></td><td><p>100% (1/1)</p></td><td><p>100% (2/2)</p></td><td><p>67% (4/6)</p></td><td><p>80% (4/5)</p></td></tr></tbody></table><p>TN = treatment-na&iuml;ve; TE = treatment-experienced.</p><p><em>Adult patients awaiting liver transplantation - Study 2025 </em></p><p>Sofosbuvir was studied in HCV infected patients prior to undergoing liver transplantation in an open-label clinical study evaluating the safety and efficacy of sofosbuvir and ribavirin administered pre-transplant to prevent post-transplant HCV reinfection. The primary endpoint of the study was post-transplant virologic response (pTVR, HCV RNA &lt;LLOQ at 12 weeks post-transplant). HCV infected patients, regardless of genotype, with hepatocellular carcinoma (HCC) meeting the MILAN criteria received 400 mg sofosbuvir and 1,000-1,200 mg ribavirin daily for a maximum of 24 weeks, subsequently amended to 48 weeks, or until the time of liver transplantation, whichever occurred first. An interim analysis was conducted on 61 patients who received sofosbuvir and ribavirin; the majority of patients had HCV genotype 1, 44 patients were CPT class A and 17 patients were CPT class B. Of these 61 patients, 44 patients underwent liver transplantation following up to 48 weeks of treatment with sofosbuvir and ribavirin; 41 had HCV RNA &lt;LLOQ at the time of transplantation. The virologic response rates of the 41 patients transplanted with HCV RNA &lt;LLOQ is described in Table 19. Duration of viral suppression prior to transplantation was the most predictive factor for pTVR in those who were HCV RNA &lt;LLOQ at the time of transplantation.</p><p><strong>Table 19: Virologic response post-transplant in patients with HCV RNA &lt;LLOQ at the time of liver transplantation </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td><p><strong>Week 12 </strong></p><p><strong>post-transplant (pTVR)<sup>b </sup></strong></p></td></tr><tr><td><p>Virologic response in evaluable patients<sup>a</sup></p></td><td><p>23/37 (62%)</p></td></tr></tbody></table><p>a. Evaluable patients are defined as those who have reached the specified time point at the time of the interim analysis.</p><p>b. pTVR: post-transplant virologic response (HCV RNA &lt;LLOQ at 12 weeks post-procedure).</p><p>In patients that discontinued therapy at 24 weeks, according to protocol, the relapse rate was 11/15.</p><p><em>Adult liver transplant recipients - Study 0126 </em></p><p>Sofosbuvir was studied in an open-label clinical study evaluating the safety and efficacy of 24 weeks of treatment with sofosbuvir and ribavirin in liver transplant recipients with chronic hepatitis C. Eligible patients were &ge;18 years old and had undergone liver transplantation 6 to 150 months prior to screening. Patients had HCV RNA &ge;104 IU/mL at screening and documented evidence of chronic HCV infection pre-transplantation. The starting dose of ribavirin was 400 mg given in a divided daily dose. If patients maintained haemoglobin levels &ge;12 g/dL, ribavirin dose was increased at weeks 2, 4, and up to every 4 weeks until the appropriate weight-based dose was reached (1,000 mg daily in patients &lt;75 kg, 1,200 mg daily in patients &ge;75 kg). The median ribavirin dose was 600 mg-800 mg daily at weeks 4-24.</p><p>Forty patients (33 with HCV genotype 1 infection, 6 with HCV genotype 3 infection, and 1 with HCV genotype 4 infection) were enrolled, 35 of whom had previously failed interferon-based treatment, and 16 of whom had cirrhosis. 28 out of 40 (70%) patients achieved SVR12: 22/33 (73%) with HCV genotype 1 infection, 6/6 (100%) with HCV genotype 3 infection, and 0/1 (0%) with HCV genotype 4 infection. All patients who achieved SVR12 achieved SVR24 and SVR48.</p><p><u>Overview of outcomes by therapeutic regimen and treatment duration, a comparison across studies </u></p><p>The following tables (Table 20 to Table 23) present data from Phase 2 and Phase 3 studies relevant to the dosing to help clinicians determine the best regimen for individual patients.</p><p><strong>Table 20: Outcomes by therapeutic regimen and treatment duration, a comparison across studies in genotype 1 HCV infection </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Patient population</strong></p><p><strong>(Study number/name) </strong></p></td><td style="vertical-align:top"><p><strong>Regimen/Duration </strong></p></td><td style="vertical-align:top"><p><strong>Subgroup </strong></p></td><td style="vertical-align:top"><p><strong>SVR12 rate % (n/N) </strong></p></td></tr><tr><td rowspan="5"><p>Treatment-na&iuml;ve<sup>a</sup></p><p>(NEUTRINO)</p></td><td rowspan="5"><p>SOF+PEG+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>90% (262/292)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1a</p></td><td style="vertical-align:top"><p>92% (206/225)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1b</p></td><td style="vertical-align:top"><p>83% (55/66)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td style="vertical-align:top"><p>93% (253/273)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top"><p>80% (43/54)</p></td></tr><tr><td rowspan="5"><p>Treatment-na&iuml;ve and co-infected with HIV</p><p>(PHOTON-1)</p></td><td rowspan="5"><p>SOF+RBV 24 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>76% (87/114)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1a</p></td><td style="vertical-align:top"><p>82% (74/90)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1b</p></td><td style="vertical-align:top"><p>54% (13/24)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td style="vertical-align:top"><p>77% (84/109)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top"><p>60% (3/5)</p></td></tr><tr><td rowspan="5"><p>Treatment-na&iuml;ve</p><p>(QUANTUMb and 11-1-0258<sup>b</sup>)</p></td><td rowspan="5"><p>SOF+RBV 24 weeks</p></td><td style="vertical-align:top"><p>Overall<sup>c</sup></p></td><td style="vertical-align:top"><p>65% (104/159)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1a<sup>c</sup></p></td><td style="vertical-align:top"><p>69% (84/121)</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1b<sup>c</sup></p></td><td style="vertical-align:top"><p>53% (20/38)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis<sup>c</sup></p></td><td style="vertical-align:top"><p>68% (100/148)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis<sup>c</sup></p></td><td style="vertical-align:top"><p>36% (4/11)</p></td></tr></tbody></table><p>n = number of patients with SVR12 response; N = total number of patients per group.</p><p>a. For previously treated patients with genotype 1 HCV infection, no data exists with the combination of sofosbuvir, peginterferon alfa and ribavirin. Consideration should be given to treating these patients, and potentially extending the duration of therapy with sofosbuvir, peginterferon alfa and ribavirin beyond 12 weeks and up to 24 weeks; especially for those subgroups who have one or more factors historically associated with lower response rates to interferon-based therapies (prior null response to peginterferon alfa and ribavirin therapy, advanced fibrosis/cirrhosis, high baseline viral concentrations, black race, IL28B non CC genotype).</p><p>b. These are exploratory or Phase 2 studies. The outcomes should be interpreted with caution, as subject numbers are small and SVR rates may be impacted by the selection of patients.</p><p>c. Summary data from both studies.</p><p><strong>Table 21: Outcomes by therapeutic regimen and treatment duration, a comparison across studies in genotype 2 HCV infection </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Patient population</strong></p><p><strong>(Study number/name) </strong></p></td><td style="vertical-align:top"><p><strong>Regimen/Duration </strong></p></td><td style="vertical-align:top"><p><strong>Subgroup </strong></p></td><td style="vertical-align:top"><p><strong>SVR12 rate % (n/N) </strong></p></td></tr><tr><td rowspan="3"><p>Treatment-na&iuml;ve</p><p>(FISSION)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>95% (69/73)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>97% (59/61)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>83% (10/12)</p></td></tr><tr><td rowspan="3"><p>Interferon intolerant, ineligible or unwilling</p><p>(POSITRON)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>93% (101/109)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>92% (85/92)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>94% (16/17)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(FUSION)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>82% (32/39)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>90% (26/29)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>60% (6/10)</p></td></tr><tr><td rowspan="3"><p>Treatment-na&iuml;ve</p><p>(VALENCE)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>97% (31/32)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>97% (29/30)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>100% (2/2)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(VALENCE)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>90% (37/41)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>91% (30/33)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>88% (7/8)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(FUSION)</p></td><td rowspan="3"><p>SOF+RBV 16 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>89% (31/35)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>92% (24/26)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>78% (7/9)</p></td></tr><tr><td rowspan="3"><p>Treatment-na&iuml;ve co-infected with HIV</p><p>(PHOTON-1)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>88% (23/26)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>88% (22/25)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>100% (1/1)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced co-infected with HIV</p><p>(PHOTON-1)</p></td><td rowspan="3"><p>SOF+RBV 24 weeks</p></td><td style="vertical-align:top"><p>Overall<sup>a</sup></p></td><td><p>93% (14/15)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis<sup>a</sup></p></td><td><p>92% (12/13)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis<sup>a</sup></p></td><td><p>100% (2/2)</p></td></tr><tr><td><p>Treatment-na&iuml;ve</p><p>(ELECTRON<sup>b</sup> and PROTON<sup>b</sup>)</p></td><td><p>SOF+PEG+RBV 12 weeks</p></td><td><p>Overall<sup>c</sup></p></td><td><p>96% (25/26)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(LONESTAR-2<sup>b</sup>)</p></td><td rowspan="3"><p>SOF+PEG+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>96% (22/23)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>100% (9/9)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>93% (13/14)</p></td></tr></tbody></table><p>n = number of patients with SVR12 response; N = total number of patients per group.</p><p>a. These data are preliminary.</p><p>b. These are exploratory or Phase 2 studies. The outcomes should be interpreted with caution, as subject numbers are small and SVR rates may be impacted by the selection of patients. In the ELECTRON study (N = 11), the duration of peginterferon alfa ranged from 4-12 weeks in combination with sofosbuvir + ribavirin.</p><p>c. All patients were non-cirrhotic in these two studies.</p><p><strong>Table 22: Outcomes by therapeutic regimen and treatment duration, a comparison across studies in genotype 3 HCV infection </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Patient population</strong></p><p><strong>(Study number/name) </strong></p></td><td style="vertical-align:top"><p><strong>Regimen/Duration </strong></p></td><td style="vertical-align:top"><p><strong>Subgroup </strong></p></td><td style="vertical-align:top"><p><strong>SVR12 rate % (n/N) </strong></p></td></tr><tr><td rowspan="3"><p>Treatment-na&iuml;ve</p><p>(FISSION)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>56% (102/183)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>61% (89/145)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>34% (13/38)</p></td></tr><tr><td rowspan="3"><p>Interferon intolerant, ineligible or unwilling</p><p>(POSITRON)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>61% (60/98)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>68% (57/84)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>21% (3/14)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(FUSION)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>30% (19/64)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>37% (14/38)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>19% (5/26)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(FUSION)</p></td><td rowspan="3"><p>SOF+RBV 16 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>62% (39/63)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>63% (25/40)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>61% (14/23)</p></td></tr><tr><td rowspan="3"><p>Treatment-na&iuml;ve</p><p>(VALENCE)</p></td><td rowspan="3"><p>SOF+RBV 24 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>93% (98/105)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>94% (86/92)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>92% (12/13)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(VALENCE)</p></td><td rowspan="3"><p>SOF+RBV 24 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>77% (112/145)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>85% (85/100)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>60% (27/45)</p></td></tr><tr><td rowspan="3"><p>Treatment-na&iuml;ve co-infected with HIV</p><p>(PHOTON-1)</p></td><td rowspan="3"><p>SOF+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>67% (28/42)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>67% (24/36)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>67% (4/6)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced co-infected with HIV</p><p>(PHOTON-1)</p></td><td rowspan="3"><p>SOF+RBV 24 weeks</p></td><td style="vertical-align:top"><p>Overall<sup>a</sup></p></td><td><p>92% (12/13)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis<sup>a</sup></p></td><td><p>100% (8/8)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis<sup>a</sup></p></td><td><p>80% (4/5)</p></td></tr><tr><td><p>Treatment-na&iuml;ve</p><p>(ELECTRON<sup>b</sup> and PROTON<sup>b</sup>)</p></td><td><p>SOF+PEG+RBV 12 weeks</p></td><td><p>Overall<sup>c</sup></p></td><td><p>97% (38/39)</p></td></tr><tr><td rowspan="3"><p>Treatment-experienced</p><p>(LONESTAR-2<sup>b</sup>)</p></td><td rowspan="3"><p>SOF+PEG+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td><p>83% (20/24)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td><p>83% (10/12)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td><p>83% (10/12)</p></td></tr></tbody></table><p>n = number of patients with SVR12 response; N = total number of patients per group.</p><p>a. These data are preliminary.</p><p>b. These are exploratory or Phase 2 studies. The outcomes should be interpreted with caution, as subject numbers are small and SVR rates may be impacted by the selection of patients. In the ELECTRON study (N = 11), the duration of peginterferon alfa ranged from 4-12 weeks in combination with sofosbuvir + ribavirin.</p><p>c. All patients were non-cirrhotic in these two studies.</p><p><strong>Table 23: Outcomes by therapeutic regimen and treatment duration, a comparison across studies in genotype 4, 5 and 6 HCV infection </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Patient population</strong></p><p><strong>(Study number/name) </strong></p></td><td style="vertical-align:top"><p><strong>Regimen/Duration </strong></p></td><td style="vertical-align:top"><p><strong>Subgroup </strong></p></td><td style="vertical-align:top"><p><strong>SVR12 rate % (n/N) </strong></p></td></tr><tr><td rowspan="3"><p>Treatment-na&iuml;ve</p><p>(NEUTRINO)</p></td><td rowspan="3"><p>SOF+PEG+RBV 12 weeks</p></td><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>97% (34/35)</p></td></tr><tr><td style="vertical-align:top"><p>No cirrhosis</p></td><td style="vertical-align:top"><p>100% (33/33)</p></td></tr><tr><td style="vertical-align:top"><p>Cirrhosis</p></td><td style="vertical-align:top"><p>50% (1/2)</p></td></tr></tbody></table><p>n = number of patients with SVR12 response; N = total number of patients per group.</p><p><em>Patients with renal impairment </em></p><p>Study 0154 was an open-label clinical study that evaluated the safety and efficacy of 24 weeks of treatment with sofosbuvir in combination with ribavirin in 20 genotype 1 or 3 HCV-infected patients with severe renal impairment not requiring dialysis. Following treatment with sofosbuvir 200 mg or 400 mg in combination with ribavirin the SVR12 rate in patients with ESRD was 40% and 60%, respectively. The safety and efficacy of 12 weeks of treatment with ledipasvir/sofosbuvir in 18 genotype 1 HCV-infected patients with severe renal impairment not requiring dialysis was also studied in Study 0154. At baseline, two patients had cirrhosis and the mean eGFR was 24.9 mL/min (range: 9.0-39.6). SVR12 was achieved in 100 % (18/18) of patients treated with ledipasvir/sofosbuvir.</p><p>Study 4063 was an open-label study that evaluated a fixed dose combination of sofosbuvir and ledipasvir in 95 patients with HCV-infection and ESRD requiring dialysis. The SVR rates for the 8, 12, and 24 week ledipasvir/sofosbuvir treatment groups were 93% (42/45), 100% (31/31), and 79% (15/19), respectively. Of the seven patients who did not achieve SVR12, none experienced virologic failure or relapsed.</p><p>Study 4062 was an open-label study that evaluated a fixed dose combination of sofosbuvir and velpatasvir in 59 HCV-infected patients with ESRD requiring dialysis. The SVR rate was 95% (56/59); of the three patients that did not achieve SVR12, one had completed sofosbuvir with velpatasvir treatment and relapsed.</p><p><em>Paediatric population </em></p><p>The efficacy of sofosbuvir in HCV-infected patients aged 12 to &lt;18 years was evaluated in a Phase 2, open label clinical trial that enrolled 50 patients with genotype 2 (n = 13) or genotype 3 (n = 37) chronic HCV infection. Patients with HCV genotype 2 or 3 infection in the trial were treated with sofosbuvir with ribavirin for 12 or 24 weeks, respectively.</p><p>Of the 50 treated patients, the median age was 15 years (range: 12 to 17); 42% of the patients were female; 90% were White, 4% were Black, and 2% were Asian; 4% were Hispanic/Latino; mean body mass index was 22 kg/m2 (range: 16 to 32 kg/m2); 18% were treatment experienced; 66% had baseline HCV RNA levels greater than or equal to 800,000 IU/mL; 74% of patients had non-CC IL28B alleles (CT or TT); and no patients had known cirrhosis. The majority of patients (69%) had been infected through vertical transmission.</p><p>The SVR12 rate was 100% (13/13) in genotype 2 patients and 97% (36/37) in genotype 3 patients. No patient experienced on-treatment virologic failure or relapse. One patient with genotype 3 HCV infection achieved SVR4 but did not return for the SVR12 visit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sofosbuvir is a nucleotide prodrug that is extensively metabolised. The active metabolite is formed in hepatocytes and not observed in plasma. The predominant (&gt;90%) metabolite, GS-331007, is inactive. It is formed through sequential and parallel pathways to the formation of active metabolite.</p><p><u>Absorption </u></p><p>The pharmacokinetic properties of sofosbuvir and the predominant circulating metabolite GS-331007 have been evaluated in healthy adult subjects and in patients with chronic hepatitis C. Following oral administration, sofosbuvir was absorbed quickly and the peak plasma concentration was observed ~0.5-2 hour post-dose, regardless of dose level. Peak plasma concentration of GS-331007 was observed between 2 to 4 hours post-dose. Based on population pharmacokinetic analysis in patients with genotypes 1 to 6 HCV infection (n = 986), steady-state AUC0-24 for sofosbuvir and GS-331007 was 1,010 ng&bull;h/mL and 7,200 ng&bull;h/mL, respectively. Relative to healthy subjects (n = 284), the sofosbuvir and GS-331007 AUC0-24 was 57% higher and 39% lower, respectively in HCV infected patients.</p><p><em>Effects of food </em></p><p>Relative to fasting conditions, the administration of a single dose of sofosbuvir with a standardised high fat meal slowed the rate of absorption of sofosbuvir. The extent of absorption of sofosbuvir was increased approximately 1.8-fold, with little effect on peak concentration. The exposure to GS-331007 was not altered in the presence of a high-fat meal.</p><p><u>Distribution </u></p><p>Sofosbuvir is not a substrate for hepatic uptake transporters, organic anion-transporting polypeptide (OATP) 1B1 or 1B3, and organic cation transporter (OCT) 1. While subject to active tubular secretion, GS-331007 is not a substrate for renal transporters including organic anion transporter (OAT) 1 or 3, OCT2, MRP2, P-gp, BCRP or MATE1. Sofosbuvir and GS-331007 are not inhibitors of drug transporters P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3 and OCT1. GS-331007 is not an inhibitor of OAT1, OCT2, and MATE1.</p><p>Sofosbuvir is approximately 85% bound to human plasma proteins (ex vivo data) and the binding is independent of drug concentration over the range of 1 &mu;g/mL to 20 &mu;g/mL. Protein binding of GS-331007 was minimal in human plasma. After a single 400 mg dose of [14C]-sofosbuvir in healthy subjects, the blood to plasma ratio of 14C-radioactivity was approximately 0.7.</p><p><u>Biotransformation </u></p><p>Sofosbuvir is extensively metabolised in the liver to form the pharmacologically active nucleoside analog triphosphate GS-461203. The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester moiety catalysed by human cathepsin A (CatA) or carboxylesterase 1 (CES1) and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 (HINT1) followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway. Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity in vitro. Sofosbuvir and GS-331007 are not substrates or inhibitors of UGT1A1 or CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 enzymes.</p><p>After a single 400 mg oral dose of [14C]-sofosbuvir, sofosbuvir and GS-331007 accounted for approximately 4% and &gt;90% of drug-related material (sum of molecular weight-adjusted AUC of sofosbuvir and its metabolites) systemic exposure, respectively.</p><p><u>Elimination </u></p><p>Following a single 400 mg oral dose of [14C]-sofosbuvir, mean total recovery of the dose was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, faeces, and expired air, respectively. The majority of the sofosbuvir dose recovered in urine was GS-331007 (78%) while 3.5% was recovered as sofosbuvir. This data indicate that renal clearance is the major elimination pathway for GS-331007 with a large part actively secreted. The median terminal half-lives of sofosbuvir and GS-331007 were 0.4 and 27 hours respectively.</p><p><u>Linearity/non-linearity </u></p><p>The dose linearity of sofosbuvir and its primary metabolite, GS-331007, was evaluated in fasted healthy subjects. Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 400 mg.</p><p><u>Pharmacokinetics in special populations </u></p><p><em>Gender and race </em></p><p>No clinically relevant pharmacokinetic differences due to gender or race have been identified for sofosbuvir and GS-331007.</p><p><em>Elderly </em></p><p>Population pharmacokinetic analysis in HCV infected patients showed that within the age range (19 to 75 years) analysed, age did not have a clinically relevant effect on the exposure to sofosbuvir and GS-331007. Clinical studies of sofosbuvir included 65 patients aged 65 and over. The response rates observed for patients over 65 years of age were similar to that of younger patients across treatment groups.</p><p><em>Renal impairment </em></p><p>A summary of the effect of varying degrees of renal impairment (RI) on the exposures of sofosbuvir and GS-331007 compared to subjects with normal renal function, as described in the text below, are provided in Table 24.</p><p><strong>Table 24: Effect of varying degrees of renal impairment on exposures (AUC) of sofosbuvir and GS-331007 compared to subjects with normal renal function </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="3" style="vertical-align:top">&nbsp;</td><td colspan="5" style="vertical-align:top"><p><strong>HCV-Negative Subjects </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HCV-Infected Subjects </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Mild RI</p><p>(eGFR &ge;50 and &lt;80 mL/min/1.73m2)</p></td><td rowspan="2" style="vertical-align:top"><p>Moderate RI</p><p>(eGFR &ge;30 and &lt;50 mL/min/1.73m2)</p></td><td rowspan="2" style="vertical-align:top"><p>Severe RI</p><p>(eGFR &lt;30 mL/min/1.73m2)</p></td><td colspan="2" style="vertical-align:top"><p>ESRD Requiring Dialysis</p></td><td rowspan="2" style="vertical-align:top"><p>Severe RI</p><p>(eGFR &lt;30 mL/min/1.73m2)</p></td><td rowspan="2" style="vertical-align:top"><p>ESRD Requiring Dialysis</p></td></tr><tr><td style="vertical-align:top"><p>Dosed 1 hr Before Dialysis</p></td><td style="vertical-align:top"><p>Dosed 1 hr After Dialysis</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir</p></td><td><p>1.6-fold&uarr;</p></td><td><p>2.1-fold&uarr;</p></td><td><p>2.7-fold&uarr;</p></td><td><p>1.3-fold&uarr;</p></td><td><p>1.6-fold&uarr;</p></td><td><p>~2-fold&uarr;</p></td><td><p>1.9-fold&uarr;</p></td></tr><tr><td style="vertical-align:top"><p>GS-331007</p></td><td><p>1.6-fold&uarr;</p></td><td><p>1.9-fold&uarr;</p></td><td><p>5.5-fold&uarr;</p></td><td><p>&ge;10-fold&uarr;</p></td><td><p>&ge;20-fold&uarr;</p></td><td><p>~7-fold&uarr;</p></td><td><p>21-fold&uarr;</p></td></tr></tbody></table><p>&nbsp;</p><p>The pharmacokinetics of sofosbuvir were studied in HCV negative patients with mild (eGFR &ge;50 and &lt;80 mL/min/1.73 m2), moderate (eGFR &ge;30 and &lt;50 mL/min/1.73 m2), severe renal impairment (eGFR &lt;30 mL/min/1.73 m2) and patients with ESRD requiring haemodialysis following a single 400 mg dose of sofosbuvir, relative to patients with normal renal function (eGFR &gt;80 mL/min/1.73 m2). GS-331007 is efficiently removed by haemodialysis with an extraction coefficient of approximately 53%. Following a single 400 mg dose of sofosbuvir, a 4 hour haemodialysis removed 18% of administered sofosbuvir dose.</p><p>In HCV-infected patients with severe renal impairment treated with sofosbuvir 200 mg with ribavirin (n=10) or sofosbuvir 400 mg with ribavirin (n=10) for 24 weeks or ledipasvir/sofosbuvir 90/400 mg (n=18) for 12 weeks, the pharmacokinetics of sofosbuvir and GS-331007 were consistent with that observed in HCV negative patients with severe renal impairment.</p><p>The pharmacokinetics of sofosbuvir, and GS-331007 were studied in HCV-infected patients with ESRD requiring dialysis treated with ledipasvir/sofosbuvir (n = 94) for 8, 12, or 24 weeks or sofosbuvir/velpatasvir (n = 59) for 12 weeks, and compared to patients without renal impairment in the ledipasvir/sofosbuvir and sofosbuvir/velpatasvir Phase 2/3 trials (see section 4.4).</p><p><em>Hepatic impairment </em></p><p>The pharmacokinetics of sofosbuvir were studied following 7-day dosing of 400 mg sofosbuvir in HCV infected patients with moderate and severe hepatic impairment (CPT class B and C). Relative to patients with normal hepatic function, the sofosbuvir AUC0-24 was 126% and 143% higher in moderate and severe hepatic impairment, while the GS-331007 AUC0-24 was 18% and 9% higher, respectively. Population pharmacokinetics analysis in HCV infected patients indicated that cirrhosis had no clinically relevant effect on the exposure to sofosbuvir and GS-331007. No dose adjustment of sofosbuvir is recommended for patients with mild, moderate and severe hepatic impairment (see section 4.2).</p><p><em>Paediatric population </em></p><p>Sofosbuvir and GS-331007 exposures in adolescents aged 12 to &lt;18 years were similar to those in adults from Phase 2/3 studies following administration of sofosbuvir (400 mg). The pharmacokinetics of sofosbuvir and GS-331007 have not been established in paediatric patients &lt; 12 years of age.</p><p><u>Pharmacokinetic/pharmacodynamic relationship(s) </u></p><p>Efficacy, in terms of rapid virologic response, has been shown to correlate with exposure to sofosbuvir as well as GS 331007. However, neither of these entities has been evidenced to be a general surrogate marker for efficacy (SVR12) at the therapeutic 400 mg dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat dose toxicology studies in rat and dog, high doses of the 1:1 diastereomeric mixture caused adverse liver (dog) and heart (rat) effects and gastrointestinal reactions (dog). Exposure to sofosbuvir in rodent studies could not be detected likely due to high esterase activity; however, exposure to the major metabolite GS-331007 at the adverse dose was 29 times (rat) and 123 times (dog) higher than the clinical exposure at 400 mg sofosbuvir. No liver or heart findings were observed in chronic toxicity studies at exposures 9 times (rat) and 27 times (dog) higher than the clinical exposure.</p><p>Sofosbuvir was not genotoxic in a battery of in vitro or in vivo assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes and in vivo mouse micronucleus assays.</p><p>Carcinogenicity studies in mice and rats do not indicate any carcinogenicity potential of sofosbuvir administered at doses up to 600 mg/kg/day in mouse and 750 mg/kg/day in rat. Exposure to GS-331007 in these studies was up to 30 times (mouse) and 15 times (rat) higher than the clinical exposure at 400 mg sofosbuvir.</p><p>Sofosbuvir had no effects on embryo-foetal viability or on fertility in rat and was not teratogenic in rat and rabbit development studies. No adverse effects on behaviour, reproduction or development of offspring in rat were reported. In rabbit studies exposure to sofosbuvir was 9 times the expected clinical exposure. In the rat studies, exposure to sofosbuvir could not be determined but exposure margins based on the major human metabolite ranged from 8 to 28 times higher than the clinical exposure at 400 mg sofosbuvir.</p><p>Sofosbuvir-derived material was transferred through the placenta in pregnant rats and into the milk of lactating rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core </u></p><p>Mannitol</p><p>Microcrystalline cellulose</p><p>Croscarmellose sodium</p><p>Colloidal anhydrous silica</p><p>Magnesium stearate</p><p><u>Film-coating </u></p><p>Opadry 85F 92259 Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SOVIRA tablets are supplied in a carton box containing plastic HDPE bottle (containing 28 films-coated), desiccant and leaflet. The plastic bottle is aluminium sealed and closed with a plastic HDPE cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim pharmaceutical plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2021.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>